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The purpose of this thesis is to review the concept of cerebral autoregulation, to establish the 
feasibility of continuous bedside monitoring of autoregulation, and to examine the impact of 
impaired autoregulation on functional and clinical outcomes following subarachnoid hemorrhage 
and ischemic stroke. Autoregulation plays a key role in the regulation of brain blood flow and has 
been shown to fail in acute brain injury. Disturbed autoregulation may lead to secondary brain 
injury as well as worse outcomes. Furthermore, there exist several methodologies, both invasive 
and non-invasive, for the continuous assessment of autoregulation in individual patients. Resultant 
autoregulatory parameters of brain blood flow can be harnessed to derive optimal cerebral perfusion 
pressures, which may be targeted to achieve better outcomes. Multiple studies in adults and several 
in children have highlighted the feasibility of individualizing mean arterial pressure in this fashion.  
 
The thesis herein argues for the high degree of translatability of this personalized approach within 
the neuroscience intensive care unit, while underscoring the clinical import of autoregulation 
monitoring in critical care patients. In particular, this document recapitulates findings from two 
separate, prospectively enrolled patient groups with subarachnoid hemorrhage and ischemic stroke, 
elucidating how deviation from dynamic and personalized blood pressure targets associates with 
worse outcome in each cohort. While definitive clinical benefits remain elusive (pending 
randomized controlled trials), autoregulation-guided blood pressure parameters wield great 
potential for constructing an ideal physiologic environment for the injured brain.  
 
The first portion of this thesis discusses basic autoregulatory physiology as well as various tools to 
interrogate the brain’s pressure reactivity at the bedside. It then reviews the development of the 
optimal cerebral perfusion pressure as a biological hemodynamic construct. The second chapter 
pertains to the clinical applications of bedside neuromonitoring in patients with aneurysmal 
subarachnoid hemorrhage. In this section, the personalized approach to blood pressure monitoring 
is discussed in greater detail. Finally, in the third chapter, a similar autoregulation-oriented blood 
pressure algorithm is applied to a larger cohort of patients with ischemic stroke. This section 
contends that our novel, individualized strategy to hemodynamic management in stroke patients 
represents a better alternative to the currently endorsed practice of maintaining systolic blood 
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A. Introduction: a brief history of autoregulation research 
 
In 1959, Dr. Niels Lassen published a pivotal review on cerebral blow flow and popularized 
the concept of cerebral autoregulation. [1] He writes, “Until about 1930 the cerebral 
circulation was generally believed to vary passively with changes in the perfusion pressure. 
This concept was based mainly on the Monro-Kellie doctrine of a constant volume of the 
intracranial contents, from which it was deduced that no significant changes in intracranial 
blood volume or vascular diameter were likely to occur.” In fact, Monro promoted this 
conceit regarding the skull’s non-compliance in 1783, and it wasn’t until 1890 that Roy 
and Sherrington submitted that cerebral blood flow might be dependent on both arterial 
pressure in conjunction with intrinsic cerebrovascular properties capable of autonomously 
regulating flow. [2, 3] In their letter to the Journal of Physiology, the authors speculate on 
the origins of these properties:  
 
“Presumably, when the activity of the brain is not great, its blood-supply is 
regulated mainly by the intrinsic mechanism and without notable interference with 
the blood-supply of other organs and tissues. When, on the other hand, the cerebral 
activity is great, or when the circulation of the brain is interfered with, the 
vasomotor nerves are called into action, the supply of blood to other organs of the 
body being thereby trenched upon.” 
 
 
Then, in 1902, Sir W.M. Bayliss performed a series of experiments on anesthetized cats, 
dogs, and rabbits, observing peripheral vasoconstriction during increased blood pressure 
inductions. [4] In a sample of his meticulous tracings below, one can appreciate that after 
excitation of the splanchnic nerve, arterial pressure rises and causes passive distention of 
hindleg volume (Figure 1). Bayliss points out that instead of merely returning to its original 
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volume when the blood pressure returns to baseline, the volume of the limb constricts 
considerably below its previous level before returning to normal. This phenomenon was 
later dubbed the Bayliss effect, referring to a pressure-reactive, myogenic vascular system.  
 
 
Figure 1. Exemplary myogenic reactivity as demonstrated by W.M. Bayliss 
at the turn of the 20th century. [4] 
 
In the ensuing decades leading up to Lassen’s review, quantitative studies in both animal 
models and humans confirmed observations of autoregulation as an objective homeostatic 
phenomenon, first described by Forbes in 1928 and later by Fog in 1938. [5-8] Through 
direct observation of feline pial vessels through a pioneering cranial window (a so-called 
lucite calvarium), they noticed that systemic blood pressure increases resulted in surface 
vessel vasoconstriction, while pressure decrements yielded local vasodilation, thus 
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sustaining the Bayliss effect. In summarizing these studies, Lassen found that optimal and 
constant cerebral blood flow tended to occur within a cerebral perfusion pressure range of 
roughly 50 to 150 mmHg. This autoregulatory doctrine has now made its way to first-year 
medical school classrooms and can be heard on neurocritical care rounds on a virtually 
daily basis (Figure 2).  
 
 
Figure 2. The evolution of the autoregulatory curve from Lassen’s original 
1959 publication (left) to the instructive illustration that can be found in 
First Aid for the USMLE Step 1 (right). [1]  
 
 
Furthermore, in 2019, animal model researchers in Belgium have effectively cast the lucite 
calvarium into the realm of modern translation medicine. Using a porcine cranial window, 
Klein et al. used laser Doppler flow to measure pial arteriole diameter and erythrocyte 
velocity, allowing the team to quantify cerebrovascular autoregulation and its limits 
(Figure 3). [9] The development of such models has the potential to help close the 





Figure 3. Adapted from Klein et al., this figure illustrates in vivo 
measurements of pial arteriole red blood cell flux. (a) Microscope 
positioned over the porcine cranial window with cortical laser Doppler 
probe (white) and intraparenchymal ICP-PbtO2 probe (orange) placed 
ipsilaterally behind the cranial window. (c) Fluorescent-labeled erythrocyte 
moving through a pial arteriole at 200 frames/second. (d) Baseline 
visualization of pial arterioles and individual red cell tracks. Individual red 
blood cell tracks are superimposed on the original frame in different colors. 
(e) Vasodilation of pial arterioles and individual red blood cell tracks during 




Clearly, science has evolved, but the definition of autoregulation has remained constant 
(much like the plateau of Lassen’s curve). Cerebral autoregulation is the cerebrovascular 
tree’s intrinsic capacity to maintain a stable blood flow despite changes in blood pressure 
or – more accurately – cerebral perfusion pressure. [10] In his report, Lassen observes that 
5 
 
cerebral perfusion pressures vary to a modest extent in a normal person and that “the most 
important regulating factor probably [is] the tissue carbon dioxide tensions and the direct 
reaction of the muscular cells of the cerebral arteries in response to variations of the 
distending blood pressure.” [1] Indeed, under normal circumstances, cerebral blood flow 
is regulated through changes in arteriolar diameter, which, in turn, drive changes in 
cerebrovascular resistance in accordance with the Hagen-Poiseuille equation. [11] 
Although decades of subsequent research have illuminated some underpinning 
mechanisms, the exact molecular means underlying autoregulation remain elusive. Various 
processes, including myogenic, neurogenic, endothelial, and metabolic responses, have 
been implicated in the mediation of cerebral vasomotor reactions, but it is important to 
differentiate carbon dioxide reactivity and flow-metabolism coupling from cerebral 
autoregulation. [12] Carbon dioxide reactivity describes vascular reactions in response to 
changes in the partial pressure of arterial carbon dioxide (PaCO2) but does not take into 
consideration reactions to pressure changes. Flow-metabolism coupling, in comparison, 
involves regulation of cerebral blood flow with regard to local cellular demand, for 
example, as a consequence of neural activation during cognitive tasks. Similar to PaCO2 
reactivity, flow-metabolism coupling and the neurovascular unit function irrespective of 
fluctuations in cerebral perfusion pressure. [11] 
 
With a working definition of autoregulation and an understanding of what it is not, 
researchers have built technology that now boasts the ability to collect autoregulation-
derived data in real-time, which may lead to the fine-tuning of decades-old guidelines. [13, 
14] By individualizing cerebral perfusion pressure in the neurocritical care unit, updated 
guidelines may potentially ameliorate clinical and functional outcomes. [15] 
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Autoregulation can now efficaciously be assessed by examining changes in cerebral blood 
flow, or its surrogates, in response to changes in cerebral perfusion pressure, or mean 
arterial pressure (MAP) as its surrogate. [11] Individualization of autoregulatory pressure 
ranges, together with the developing concept of an optimum mean arterial pressure 
landscape for the injured brain, represent a novel and innovate application of autoregulation 
neuromonitoring.  
 
Numerous studies in recent years have demonstrated that large differences between actual 
MAP and an optimal, calculated MAP (based on autoregulatory status) associate with poor 
outcome across several disease states. These papers encompass traumatic brain injury, 
intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke, adults undergoing 
cardiac bypass surgery, children with moyamoya vasculopathy, and neonates with 
hypoxic-ischemic encephalopathy. [13, 16-22] The cumulative strength of these findings 
triggered the Brain Trauma Foundation to recommend autoregulation monitoring in an 
effort to optimize brain perfusion in patients with traumatic brain injury. [23] 
 
Nevertheless, guidelines for blood pressure management persistently recommend a single, 
fixed target value for many critically ill patients. For example, the American Heart 
Association and American Stroke Association endorse a systolic blood pressure of less 
than 140 mmHg after intracerebral hemorrhage; they also suggest systolic pressures under 
160 mmHg before aneurysm obliteration, and less than 140 mmHg after clipping or coiling 
of the aneurysm following a subarachnoid hemorrhage. [24, 25] The same societies 
recommend systolic readings of less than 180 mmHg after intravenous recombinant tissue 
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plasminogen activator for ischemic stroke. [26] In contrast, the European Society of 
Intensive Care Medicine acknowledges that septic patients with a history of hypertension 
may have autoregulation curves shifted to the right, thus requiring a higher MAP for 
adequate cerebral perfusion. [27] These guidelines, however, do not currently consider 
autoregulation-guided hemodynamic management of critically ill patients. In this 
omission, many questions in the field of neuromonitoring are left unanswered. [15] First 
and foremost, with respect to this thesis, is it feasible to effectively personalize MAP 
targets based on an individual’s dynamic autoregulatory composition? Might this method 
be clinically beneficial? How can it be tailored across various monitoring techniques and 
disease states? 
 
Notwithstanding such unanswered questions, the science of autoregulation has come a long 
way since 1959. [1] Speaking perhaps to the incremental, and yet potentially 
groundbreaking nature of scientific investigation, Dr. Lassen concludes his 56-page review 
with the following remarks:  
 
“These major findings and the wealth of additional observations have very 
substantially increased our understanding of this important area of human 
physiology. Undoubtedly our knowledge is still incomplete at various points. 
However, a solid foundation for relevant physiological thinking and for future 
studies has been established.”  
 
It is now 60 years down the line, and autoregulation research is at the precipice of tangibly 
translatable use at the bedside, as clinical trials of autoregulation-guided therapy are 
underway across Europe (NCT02982122). [28] Moreover, this thesis will discuss two 
prospective, observational studies at Yale-New Haven Hospital, each investigating the 
feasibility of using an innovative algorithm to determine personalized, autoregulation-
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based blood pressure targets at the bedside. To our knowledge, these studies are the first to 
examine the impact of deviation from personalized, autoregulation-based blood pressure 
limits in patients with subarachnoid hemorrhage and large-vessel occlusion ischemic 
stroke. [13, 14] Thus, these studies arguably set the stage for imminent interventional trials 
within Yale’s Divisions of Vascular Neurology as well as Neurocritical Care and 
Emergency Neurology. [29] Before delving into the details of these studies, it is important 
to more meticulously review autoregulation physiology, monitoring techniques, and the 
development of the optimal cerebral perfusion pressure. In doing so, perhaps Lassen’s solid 
foundation will grow, and future studies will be all the more within reach.  
 
B. Cerebral blood flow regulation and physiology 
 
Cerebral oxygen delivery is a function of brain blood flow and blood oxygen content, 
whereby cerebral blood flow (CBF) is gradient between cerebral perfusion pressure (CPP) 
and cerebrovascular resistance (CVR). Another way to conceptualize blood flow to the 
brain is via the gradient between the brain’s arteries and veins, the latter being 
approximately equivalent to intracranial pressure (ICP).  
 
CBF = CPP/CVR = (MAP – ICP)/CVR 
 
The brain’s vascular resistance reflects the smooth muscle tone of the vessels, partially 
influenced by mean arterial pressure (MAP). If CPP increases or decreases, the myogenic 
reflex will result in vasoconstriction or vasodilation, respectively. This dictum is the 
classical view of pressure-flow autoregulation. If intracranial pressure is stable, CPP can 
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be replaced by MAP. In this manner, changes in brain blood flow can be measured for a 
range of blood pressures to determine autoregulation.  
 
In general, however, four mechanisms regulate cerebral blood flow, including myogenic, 
neurogenic, endothelial, and metabolic processes, illustrated in Figure 4 (ChemDraw 
Professional, Version 17.1.0.105). [10] Each of these classical mechanisms will be 
reviewed in this section, with an important caveat that the interplay and relative 
contributions of each of these mechanisms is highly complex and poorly understood. [30] 
Additionally, an imprecise border zone between conductive and resistive facets in the 
cerebrovascular tree suggests that autoregulation may involve both large and small arteries 
and arterioles. For instance, large extracranial arteries and intracranial pial vessels 
comprise roughly half of the brain’s vascular resistance, with the remainder stemming from 
penetrating parenchymal arteries and arterioles. [31, 32] These parenchymal arteries 
possess distinctive, resistive properties compared to pial vessels; ensuing segmental and 
spatiotemporal heterogeneity in autoregulation, as well as pathophysiologic correlates of 















































Figure 4. Physiology of cerebral autoregulation. This illustration shows the 
four classical mechanisms contributing to cerebral autoregulation. Through 
myogenic tone, transmural pressure influences arterial diameter through 
direct smooth muscle contraction or relaxation. In the metabolic 
mechanism, fluctuations in the partial pressure of carbon dioxide lead to 
vasoconstriction or dilatation. The endothelium secretes paracrine 
substances that may act directly on smooth muscle cells. Lastly, in the 
neurogenic response, neurons and glia mediate smooth muscle physiology 
by releasing various neurotransmitters with vasoactive properties. This 
figure was created using ChemDraw software.  
 
1) Myogenic Tone 
 
Myogenic tone is produced when arteriole and small artery smooth muscle cells 
contract in response to increased pressure. [33, 34] In contrast, myogenic tone 
relaxes in response to decreased pressure. This phenomenon is manifest in the 
aforementioned Bayliss effect (see Figure 1 in the introduction). More recent work 
11 
 
has unearthed some details about the effect. For example, a rapid change of pressure 
(ΔP = 10 to 25 mmHg/sec) induces rapid changes in the diameter of the vessel, and 
the latency of such transmural stimulation typically occurs in under 250 msec. [35]  
 
Transmural pressure changes, in turn, activate mechanically sensitive ion channels 
and proteins in the vessel wall, triggering various downstream cascades. For 
instance, membrane depolarization opens voltage-gated calcium channels, leading 
to an influx of calcium cations into the smooth muscle cell. [36] Calcium activates 
myosin light chain kinase (MLCK), which goes on to activate myosin by 
phosphorylation. Phosphorylated MLCK increases actin-myosin interaction, 
causing muscle cell contraction and vasoconstriction. Furthermore, activation of 
RhoA, a small GTPase, stimulates Rho-associated kinase (ROCK), which inhibits 
myosin light chain phosphatase. [37] Inhibiting the dephosphorylating inhibitor in 
this way potentiates vasoconstriction. Other parallel pathways involve protein 
kinase C activation, which stabilizes the actin-myosin interaction. [38] More recent 
hypotheses implicate arachidonic acid metabolites like 20-hydroxyeicosatetraenoic 
acid (20-HETE), a known vasoconstrictor, and epoxyeicosatrienoic acids (EETs) 
in the mediation of vessel wall stretch and basal tone. [39] 
 
The importance of smooth muscle cell myogenic regulation can be seen in cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL). [40, 41] Patients with CADASIL show a degree 
of smooth muscle cell degeneration in small cerebral arteries, and studies have 
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demonstrated impaired myogenic autoregulatory functioning in both animal models 
and individuals with the genetic condition. [42, 43] This disease is caused by a 
mutation in the NOTCH3 gene and marked by recurrent ischemic strokes, cognitive 
impairment, subcortical dementia, mood disturbances like depression and apathy, 
as well as premature death. Lacombe et al. provided evidence that transgenic mice 
expressing a mutant NOTCH3 in vascular smooth muscle cells exhibited impaired 
cerebral vasoreactivity, including reduced responses to vasodilatory challenges and 
a shift of the lower limit of autoregulation toward higher pressures. [44] 
Interestingly, parenchymal arteries exhibit greater basal tone than pial arteries. This 
difference may buffer effects of upstream rapid changes in blood pressure on 
cerebral perfusion and thus attenuate transmission of pulsatile mechanical stress 
into the brain’s microcirculation. Disturbance of this basal tone may exacerbate 
stroke burden in CADASIL patients. [41, 45] 
 
Increased transmural pressure translates to increased flow, and there is evidence 
that flow may induce vessel diameter changes independent of pressure changes. In 
2011, for example, Toth et al. showed that both human and rodent cerebral arteries 
constrict in response to increased flow when pressure was held constant, possibly 
due to an increase in reactive oxygen species and cyclooxygenase activity. [46]  
 
2) Neurogenic Response  
 
Neurogenic mediation of cerebral vasoreactivity involves control of small- and 
medium-sized vessel diameters. Neurons and other cell types like astrocytes and 
microglia secrete a variety of neurotransmitters with vasoactive properties. For 
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instance, acetylcholine and nitric oxide are relatively potent vasodilators, while 
serotonin and neuropeptide Y stimulate vasoconstriction. [47]  
 
Through the creative use of infrared video-microscopy of interneurons and adjacent 
microvessels in rodents, Cauli et al. showed that increased depolarizing activity of 
single cortical interneurons results in precise vasomotor responses in neighboring 
microvessels. [48] They further showed that these neuronally induced vasomotor 
responses can be mimicked by perivascular application of vasoactive neuropeptides 
directly on microvascular receptors.  
 
On a larger scale, these changes in blood flow in response to neuronal activation 
can be observed as the blood oxygen level dependent (BOLD) signal, which is 
employed in functional magnetic resonance imaging (fMRI). The BOLD response 
has been adapted in many fMRI studies investigating increased cerebral metabolic 
demand in cognitive tasks, spatial memory, visual processing, and across various 
disease states. [49-51] 
 
Interestingly, the neurogenic response exhibits both segmental and regional 
heterogeneity, as vessel reactivity varies from the pial arteries as they branch into 
the parenchyma and become arterioles. [30] Regarding segmental variability, pial 
arteries receive perivascular innervation from the peripheral autonomic system, 
with roots in the superior cervical, sphenopalatine, otic, and trigeminal ganglia. [47, 
52] This anatomic pathway is referred to as extrinsic innervation. The brain’s 
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parenchymal arteries and arterioles, in contrast, are primarily innervated by 
intrinsic nerves originating from subcortical neurons, such as those found within 
the locus coeruleus, raphe nucleus, basal forebrain, or local cortical interneurons. 
These areas then project to the perivascular space surrounding the parenchymal and 
arteriolar vessels. It follows that this pathway is referred to as intrinsic innervation.  
 
This difference in anatomy entails divergent expression levels of neurotransmitter 
receptors. For instance, α-adrenoreceptor reactivity is relatively absent in 
parenchymal arteries due to a shift toward β-adrenoreceptor density. [53] Similar 
heterogeneity has been shown with serotonin receptor levels. Accordingly, 
serotonin- and norepinephrine-induced pial vasoconstriction is absent in the 
parenchymal and arteriolar arteries, sometimes even causing vasodilation. [54] This 
mosaic topography in neurogenic regulation may provide the brain with the ability 
to flexibly modulate blood flow to meet local metabolic demand. [30] 
 
Regarding regional heterogeneity, the anterior circulatory system of the brain 
possesses denser sympathetic innervation than that of the posterior system. The 
anterior circulation is controlled mostly by adrenergic sympathetic relays from the 
superior cervical ganglion as they travel up the carotid arteries. The posterior 
vessels instead depend on the sympathetic chain via the vertebrobasilar arteries. 
[55] Autoregulation has also been shown to be more effective in the brainstem. For 
example, in severe hypertension in anesthetized cats, cerebral blood flow 
significantly increases in the anterior circulation, whereas the brainstem only 
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requires modest increases in flow. [56] This vascular resistance differential points 
to a likely regional incongruity in cerebral autoregulation.  
 
This regional variability may play a key role in the development of posterior 
reversible encephalopathy syndrome (PRES). This syndrome, which 
parenthetically is not always posterior or even reversible, is otherwise characterized 
radiologically by transient bilateral subcortical vasogenic edema in the territory of 
the posterior circulation. [57] Among several etiologic theories involving 
immunologic dysfunction, vasospasm, and endothelial and blood-brain barrier 
breakdown, one interesting explanation for the edema’s apparent posterior 
predilection is the relative dearth of sympathetic tone in that area, leading to poor 
autoregulation of blood flow in the setting of abrupt hypertensive episodes. [55] 
  
3) Metabolic Mechanism  
 
The metabolic mechanism subserving autoregulation occurs in smaller vessels that 
are subject to changes in the local environment. [58] Most notably, carbon dioxide 
overtly alters vasomotor responses; every 1 mmHg increase in PaCO2 corresponds 
to a roughly 4% increase in cerebral blood flow. [59] The concentration of cerebral 
carbon dioxide can accumulate and cause vasodilation in this fashion when, for 
example, hypotension below the lower autoregulatory limit results in tissue 
hypoperfusion and thus anaerobic respiration. The opposite physiology transpires 
in the setting of hyperperfusion with consequent decreases in PaCO2 and 




It is hypothesized that this vasomotor response is regulated by the H+ concentration 
in the smooth muscle of cerebral vessels. [59] Proton gradients are regulated by 
carbonic anhydrase activity, the catalytic activity of which depends on the tight 
regulation of pH (normally hovering around 7.4 in the human body). Prolonged 
hypocapnia that generates tissue alkalosis may increase carbonic anhydrase 
activity. [11]  
 
Additionally, decreased oxygen partial pressures can increase cerebral blood flow, 
as can be seen in Figure 2. This effect does occur unless there is severe hypoxemia 
of less than 50 mmHg, or 6.6 kPa. [62] Similarly, severe hypoglycemia at levels of 
less than 2 mmol/L can lead to increases in cerebral blood flow. [63] 
 
4) Endothelial Mechanism 
 
Lastly, endothelial tissue begets a gamut of signals that affect vascular tone. The 
endothelium secretes vasodilators like nitric oxide (NO) and vasoconstrictors like 
thromboxane A2 and endothelin-1 in a paracrine manner. [10, 64]  
 
Further, as an interesting bedside-to-bench endeavor, researchers have looked at 
the ability of statins to regulate autoregulation. In more detail, statins have the 
capacity to upregulate nitric oxide synthase, causing cerebral artery dilation and 
increased cerebral blood flow. [65, 66] This mechanism occurs through the 
inhibition of small G-proteins known as Rho and Rac. Rho negatively regulates 
endothelial nitric oxide synthase. Statins inhibit Rho GTPase activity via inhibition 
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of a process known as geranylgeranylation (a form of prenylation), which 
ultimately confers nitric oxide synthase upregulation.  
 
At this point, it should be stressed that conventional measurements of cerebrovascular 
reactivity are not exactly synonymous with measurements of cerebral autoregulation. The 
response to vasodilatory stimuli like CO2, nitric oxide, or acetazolamide, has been used 
traditionally in the quantification of vasomotor reactivity. [6, 66] These agents dilate 
cerebral arterioles and small arteries to locally increase cerebral blood flow through a 
variety of neurogenic, metabolic, and endothelial processes. Although an intact 
endothelium is quite necessary for adequate pressure regulation, this approach does not 
assess fluctuations in cerebrovascular resistance in strict response to perfusion changes. 
Therefore, vasomotor reactivity and cerebral autoregulation are non-interchangeable 
physiologic phenomena. In other words, when vasomotor reactivity is exhausted, brain 
blood flow becomes dependent on systemic arterial blood pressure. Cerebral 
autoregulation is one critical aspect of this reactivity and involves vascular tone changes in 
response to pressure fluctuations. Vessels may continue to exhibit responses to further 
changes in PaCO2, and these responses fall within the domain of the cerebral autoregulatory 
mechanism protecting the brain.  For example, vasodilation may reach its maximum at 
arterial pressures below the lower limit for constant cerebral blood flow. [6, 12] 
 
C. Methods to measure cerebral autoregulation 
 
Pressure autoregulation has traditionally been assessed by calculating cerebral blood flow 
at two different equilibrium states of arterial blood pressure. These steady-states 
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correspond to particular cerebral blood flow values. One pressure measurement could be 
taken at baseline, and the second could be measured after manual or pharmacologic 
manipulation of blood pressure, at which point brain blood flow could be measured again. 
Because this approach involves stable pressures and flows, it is referred to as a static 
autoregulatory measurement. [67] Other stimuli include body tilt, hand grip, lower body 
negative pressure, Valsalva, paced breathing, and squat-stand maneuvers. [6, 11] An 
advantage of these maneuvers is the precise control of the magnitude and time of the 
hemodynamic response; they are accurate insofar as the stimuli drive a synchronized 
response of brain blood flow. However, the methods are all temporally limited and, for the 
most part, cannot be performed more than once per day.  
 
The advent of transcranial Doppler (TCD) ultrasound allowed for visualization of real-time 
blood-flow velocities (with a temporal resolution of approximately 5 msec), paving the 
road for dynamic assessments of autoregulation. [6, 68] Dynamic autoregulation refers to 
short-term, fast responses of the brain’s blood flow to changes in systemic pressure. As 
TCD cannot measure flow directly, blood flow velocity is used as a surrogate. In this 
manner, methods like carotid compression or inflation of a leg cuff, each followed by 
release and subsequent autoregulatory hyperemia, can be utilized to induce rapid changes 
in middle cerebral artery flow velocity (taken as a surrogate for global hemispheric 
perfusion). [11, 69] Alternatively, one may insonnate intracranial vessels without any 
particular blood pressure challenges, such that monitoring takes place throughout 
spontaneous fluctuations of arterial blood pressure. [70] This latter approach renders 
dynamic assessments of cerebral autoregulation safe and feasible, as pressure 
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manipulations would be unrealistic and potentially harmful in critically ill patients. For 
example, a thigh-cuff inflation-deflation might incite a sudden blood pressure drop of up 
to 30 mmHg. [71] In a patient with an ischemic stroke, this drop could cause secondary 
brain injury from significant hypoperfusion, particularly in a setting when autoregulatory 
physiology is compromised in the first place. [13]  
 
This dynamic response is likely complete after 10-15 seconds, suggesting that arterioles 
are able to counter slower fluctuations in systemic blood pressure. Faster changes, such as 
those greater than 0.5 Hz, are not compensated – for example, those occurring with each 
cardiac systole. This selective compensation is referred to as the high-pass filter principle. 
[72] The cerebrovascular system accordingly buffers against slow hemodynamic 
oscillations (0.01 to 0.4 Hz), while higher frequencies may pass unfiltered to the brain’s 
circulation. [15] In the literature, the discussion regarding mechanisms underlying dynamic 
versus static autoregulation is ongoing. [66, 72, 73] 
 
In addition to blood flow velocity, other intracranial signals are frequently used in dynamic 
vasoregulatory research. Examples include near-infrared spectroscopy (NIRS), local brain 
tissue oxygenation (PbtO2), and intracranial pressure (ICP) monitoring from a 
cerebrospinal fluid (CSF) draining system. [74-76] The fundamental principle of these 
dynamic measurements is the same across methodologies – the input signal is a large, 
abrupt blood pressure or volume change, and the resulting change in the intracranial 
compartment acts as the output signal. [66] Analysis of these signals is discussed in the 




As NIRS was our method of choice for the studies presented in this thesis, it will be 
discussed in more detail both here and in Part II. As a primer, near-infrared light (700-950 
nanometers) is non-invasively transmitted from a source embedded in a sensor attached to 
the forehead. The light is then emitted past the skin, cranium, and cerebrospinal fluid to 
interrogate hemoglobin concentration in the frontotemporal cortex that is usually supplied 
by the middle cerebral artery. These tissues are essentially and remarkably transparent to 
light in this spectrum. [12] Many biological molecules have absorption spectra in the near-
infrared range. [77] More pertinently, these chromophores include oxyhemoglobin, 
deoxyhemoglobin, bilirubin, and cytochrome aa3 (a complex present in mitochondria that 
plays a role in the oxidative phosphorylation pathway), and they are the most abundant 
molecules that absorb light between 700 and 1,000 nm. [77, 78] The amount of light 
detected by sensors positioned at set distances from the light source is a function of 
chromophore absorption. Because oxy- and deoxyhemoglobin absorb light at different 
wavelengths, concentrations of these molecules can be derived using the modified Beer-
Lambert law. This law generally states that the absorbance of a solution (A) is equal to the 
product of the molar absorptivity (ε), the distance through which the light travels (l), and 
the concentration of the absorbing species (c), or A = εlc. Then, the ratio of oxyhemoglobin 
to total hemoglobin functions as a surrogate for cerebral blood flow, and it has been shown 
to be unaffected by extracranial circulation, hemoglobin concentration, cranial thickness, 
and cerebrospinal fluid. [79, 80] Furthermore, NIRS technology assumes that the 
hemoglobin measured is contained in a fixed mixture of vessels that are roughly 70-75% 
venous and 25-30% arterial blood volume. [12, 81] Calculations used to account for this 
21 
 
variability in the ratio of arterial to venous blood are unique to the manufacturer of the 
monitoring device. Thus, regional cerebral oxygen saturations in different machines are 
not necessarily equivalent. [82] 
 
Table 1 displays some techniques that are available for analyzing cerebral autoregulation. 
Each offer different spatiotemporal resolution, radiation exposure, usability in certain 
patient cohorts, cost and availability, as well as interpretation of output signals. [83-85] It 
should be noted that for the nuclear (positron emission tomography, or PET) and radiologic 
(CT or MRI) techniques, the temporal resolution is still insufficient for dynamic 
measurements. There has also been an absence of simultaneous, non-invasive blood 
pressure recordings alongside these radiologic measures.  
 
Table 1. Abridged comparison of cerebral autoregulation monitoring 
techniques. Pros of nuclear and radiologic methods include anatomic 
images with excellent spatial resolution, but they entail radiation as well as 
possible allergy reactions to contrast agents. They also only provide 
Methods Techniques Spatiotemporal Resolution 
Absolute or relative 
perfusion 
measurements with 




MRI with arterial spin 
labeling 
fMRI 
Excellent spatial resolution, but 
poor temporal, although arterial 
spin labeling and the BOLD 














Poor to moderate spatial 
resolution, with good temporal 
Intracranial pressure ICP monitoring Poor spatial resolution (global 




snapshot evaluations of autoregulation and are not used in patient care 
settings. Transcranial Doppler (TCD) ultrasound is relatively cheap and is 
obviously non-invasive with essentially no adverse effects (e.g., no 
radiation exposure). However, TCD offers no absolute perfusion 
measurements, and it is sometimes limited by poor window acquisition of 
the middle cerebral artery through the temporal bone. Cerebral oxygenation 
with NIRS monitoring is also non-invasive but is quite limited spatially. 
Intracranial pressure (ICP) monitoring involves excellent temporal 
resolution and can be used in conjunction with other techniques; however, 
as its name implies, it is invasive. SPECT, single photon-emission-CT.  
 
 
Most studies of cerebral autoregulation rely on linear methods (cross-spectral or 
correlation-based) to assess autoregulatory functionality and integrity. If the pressure-flow 
relationship displays low coherence, this lack of linear dependence suggests intact 
autoregulation. In other words, brain blood flow is able to resist changes in blood pressure 
with an appropriate vasoregulatory response. Nevertheless, it has been argued that 
autoregulation itself engenders uncertainty with respect to its linear estimates, and so some 
researchers have put forth non-linear analysis techniques. [30] These approaches are 
discussed in the following section on autoregulatory indices.  
 
D. Autoregulation indices and signal processing 
 
Using spontaneous fluctuations of blood pressure and cerebral blood flow, researchers have 
devised a number of mathematical methods for modeling autoregulatory indices. In this 
section, particular attention will be paid to transfer function analysis and the time-






1) Transfer Function Analysis 
 
Transfer function analysis (TFA) is based on linear, stationary modeling and a fast 
Fourier transform algorithm to compute spectral estimates of blood pressure and 
cerebral blood flow. Autoregulation, when properly functioning, attenuates the 
influence of blood pressure on brain blood flow velocity by preventing direct 
propagation of the pressure waveform at lower frequencies (usually under 0.2 Hz). 
[30] Two key parameters – gain and phase-shift – can be derived from TFA at each 
frequency. Gain reflects the compression of brain blood flow velocity amplitude 
changes in response to blood pressure. As an example, a gain of 0.65 denotes that 
65% of the relative amplitude of cerebral blood flow velocity is attenuates with 
regard to unit of change in arterial blood pressure. Phase-shift quantifies the time 
lag between blood pressure and brain flow velocity at a given frequency and is 
represented in degrees or radians. Larger phase-shifts between the two signals 
means that autoregulation is properly buffering the cerebrovascular tree from 
changes in blood pressure. [15, 86, 87] Of note, TFA can only rationalize linear 
relationships between arterial blood pressure and mean flow velocity, which is why 
coherence usually accompanies TFA to test the linearity between the two 
waveforms. Generally, a coherence above 0.5 is considered acceptable for TFA. 
Regarding frequency bands, values for gain, phase-shift, and coherence are reported 
in three bins: very low (0.02-0.07 Hz), low (0.07-0.2 Hz), and high (0.2-0.5 Hz) 
ranges. [87] The high-pass filter principle of autoregulation translates to reductions 
in coherence and gain with increases in phase-shift. These modulations result in the 
relative desynchronization between blood pressure and cerebral blood flow 
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oscillations. Additionally, because vasomotor adaptation is slow and requires 
roughly 10-15 seconds, autoregulation is most likely to function at lower 
frequencies. [6, 15, 87]  
 
2) Time Domain Analysis 
 
The moving Pearson correlation coefficient between blood pressure and various 
cerebral output signals permits the estimation of autoregulation indices with regard 
to each variable. [88] The coefficient for mean cerebral blood flow velocity is Mx, 
while the tissue oxygenation index (TOx) is derived from NIRS. Perhaps the most 
rigorously studied index is the pressure reactivity index (PRx), which is derived 
from ICP instead of cerebral blood flow velocity or tissue oxygenation. [11, 89] 
Cerebral perfusion pressure (CPP = MAP – ICP) may be substituted for arterial 
blood pressure as well. In all cases, a positive correlation coefficient reflects 
synchrony between the two signals, suggesting impaired cerebral autoregulation. 
Meanwhile, a negative or near-zero coefficient implies buffering and thus intact 
autoregulatory physiology.  
 
The use of a threshold to delineate good versus impaired autoregulation has not 
been rigorously validated in the literature. In 2014, Sorrentino et al. found that an 
autoregulatory index greater than 0.3 prognosed fatal outcome in a cohort of 459 
patients with traumatic brain injury. [90] Subsequent landmark studies adopted this 
approach when translating autoregulatory index research to individualized 
thresholds of cerebral perfusion pressure. [91] It is interesting to note that these two 
studies utilized PRx as their biomarker for autoregulation status, rather than the 
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NIRS-derived tissue oxygenation index (TOx). As stated above, PRx is derived as 
the moving correlation coefficient between ICP and mean arterial pressure, and so 
it is theoretically analogous to tissue oximetry’s continuous correlation with mean 
arterial pressure. Studies will be needed to more scrupulously compare thresholds 
for impaired autoregulation among multimodal measurements of autoregulation. 
As one example, Steiner et al. in 2009 argued that critical thresholds for the NIRS-
derived TOx should be set between 0.2 and 0.3. [92] Thus, in our studies at Yale-
New Haven Hospital, we employed the more conservative threshold, using a cutoff 
of 0.3, [13, 14] rather than 0.2 or 0.25, as some authors have done in the past. [93, 
94] Furthermore, in a piglet study using NIRS, the sensitivity and specificity of a 
NIRS-derived autoregulatory index of >0.3 to detect impaired autoregulation were 
77 and 84%, respectively. [95] Table 2 below shows more information about these 
indices in human studies, as well as their respective cutoff values for impaired 
autoregulation.  
 
3) Wavelet Analysis 
 
This approach, also known as multimodal pressure flow analysis, represents an 
alternative to the classical spectral analyses, such as fast Fourier transform, and 
considers both time and frequency content of the signal. The wavelet analysis 
produces maps of phase shift and coherence between blood pressure and cerebral 
blood flow velocity over a range of frequencies and time points. Enforcing a 
minimal coherence threshold and focusing the analysis on areas in the time-
frequency map with a high degree of correlation increases the reliability of the 
phase-shift estimation. [96] Interestingly, signal decomposition with wavelet 
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analysis has also been applied to tissue oxygenation using NIRS, paving the way 
for future wavelet signal processing using NIRS technology. [97] 
 
4) Projection Pursuit Regression 
 
Projection pursuit regression (PPR) is a non-parametric method wherein a model is 
not specified a priori but derived directly from variables of interest (i.e., arterial 
blood pressure and cerebral blood flow). This analysis modifies a linear transfer 
function between input (blood pressure) and output (brain blood flow). A linear 
autoregressive transfer function is passed through kernel functions, also known as 
ridge functions, that are determined by minimizing the mean squared error. [98] 
The method characterizes the non-linear relationship between pressure and flow 
and identifies regions wherein this relationship changes. The gain (i.e., slope) of 
the pressure-flow relationship within each region provides a measure of the 
effectiveness of autoregulation within that region. Furthermore, PPR allows for the 
derivation of five hemodynamic biomarkers of cerebral autoregulation: falling 
slope, rising slope, autoregulatory gain, as well as the upper and lower limits of 
autoregulation. An interesting 2016 study by Santos et al. used PPR to show that 
patients suffering from delayed cerebral ischemia (DCI) after subarachnoid 
hemorrhage had distinctive hemodynamic profiles with respect to those not 
suffering from DCI. [99] The authors then invoked previously found 
pharmacologic effects on PPR-derived autoregulation parameters. After combining 
their results with those parameters, the research team argued that myogenic 
dysfunction leads to vasospasm, while sympathetic overaction and cholinergic 
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dysfunction lead to DCI, while deficits in all three pathophysiologic mechanisms 
beget both vasospasm and DCI.  
 
All in all, there are over 20 indices of cerebral autoregulation, a situation with obvious pros 
and cons for autoregulation research. Each index enlists a unique threshold for impaired 
autoregulation, with a range spanning 0.069 to 0.46, depending on devices used to measure 
cerebral blood flow or a surrogate thereof. Table 2 below, adapted from an educational 
2017 review article by Rivera-Lara et al., illustrates a handful of these indices and how to 
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Table 2. Abridged comparison of autoregulation indices, how to derive 
them, and their suggested cutoff values for impaired autoregulation. MAP, 
mean arterial pressure; ICP, intracranial pressure; NIRS, near-infrared 
spectroscopy; TCD, transcranial Doppler. [100, 101] 
 
 
The time-correlation method is used to quantify TOx, Mx, PRx, and ORx. For Mx, for 
instance, a Pearson correlation coefficient is taken between 30 time-averaged (10 sec) 
values of arterial blood pressure and flow velocity. Similarly, for NIRS, a Pearson 
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correlation coefficient between 30 time-averaged (10 sec) values of arterial blood pressure 
and tissue oxygenation (TOx) or total hemoglobin concentration (THx). [15]  
 
E. Comparisons between autoregulatory indices 
 
In the past two decades, novel autoregulatory indices have been validated against more 
weathered ones. These validation studies facilitate the use of newer, possibly superior 
methods to clinically monitor autoregulation. Of greatest relevance, studies attempting to 
cross-validate invasive versus non-invasive methods wield the potential to use a non-
invasive approach in critically ill patients. Table 3 below presents a summary of said 
studies. Ultimately, the results shown appear to support the accuracy of non-invasive 
autoregulation measurements, although the number of indices available renders analytic 
standardization very challenging.  
 
Study Autoregulatory Indices Compared P Value 
Patients with no intracranial injury 
Ono et al. 2013 
[102] 
Mean flow velocity index based on MAP vs. cerebral 
oximetry index 
<0.001 
Brady et al. 2010 
[12] 
Mean flow velocity index based on MAP vs. cerebral 
oximetry index 
<0.0001 
Steiner et al. 2009 
[92] 
Mean flow velocity index based on MAP vs. tissue 
oxygen index 
<0.0001 
Hori et al. 2015 
[19] 
Mean flow velocity index based on MAP vs. cerebral 
blood flow velocity index 
<0.001 
Blaine et al. 2013 
[94] 
Mean flow velocity index based on cerebral perfusion 
pressure vs. hemoglobin volume index 
<0.001 
Patients with intracranial injuries 
Lang et al. 2003 
[101] 
Mean flow velocity index based on cerebral perfusion 
pressure vs. mean flow velocity based on MAP 
<0.01 
Sorrentino et al. 
2011 [90] 
Mean flow velocity index based on cerebral perfusion 




Lavinio et al. 
2007 [103] 
Mean flow velocity index based on cerebral perfusion 
pressure vs. mean flow velocity based on MAP 
<0.001 
Czosnyka et al. 
2008 [104] 
Mean flow velocity index based on cerebral perfusion 
pressure vs. dynamic autoregulatory index 
0.0001 
Highton et al. 
2015 [105] 
Mean flow velocity index based on MAP vs. tissue 
oxygen index 
0.004 
Soehle et al. 2004 
[70] 
Mean flow velocity index based on MAP vs. systolic 
flow velocity index 
<0.001 
Highton et al. 
2015 [105] 
Mean flow velocity index vs. tissue hemoglobin 
index 
<0.001 
Budohoski et al. 
2012 [106] 
Pressure reactivity index vs. mean flow velocity 
index based on cerebral perfusion pressure 
<0.001 
Lang et al. 2012 
[107] 
Pressure reactivity index vs. low-frequency sample 
pressure reactivity index 
<0.00001 
Santos et al. 2011 
[108] 
Pressure reactivity index vs. low-frequency sample 
pressure reactivity index 
<0.001 
Barth et al. 2010 
[109] 
Pressure reactivity index vs. brain tissue oxygen 
pressure reactivity index 
0.044 
Highton et al. 
2015 [105] 
Pressure reactivity index vs. tissue oxygen index 0.04 
Highton et al. 
2015 [105] 
Pressure reactivity index vs. tissue hemoglobin index <0.001 
Zweifel et al. 
2010 [76] 
Pressure reactivity index vs. tissue hemoglobin index 0.0002 
Silverman et al. 
2019 [14] 
Pressure reactivity index vs. tissue oxygen index <0.0001 
 




F. Optimal cerebral perfusion pressure 
 
In the last two decades, these autoregulatory indices have also been used to generate 
optimum cerebral perfusion pressures as well as ideal pressure ranges based on lower and 
upper limits of autoregulation. Steiner et al. published a landmark study in 2002 using 
continuous autoregulation monitoring as a means of identifying optimal cerebral perfusion 
pressure (CPPOPT) in patients with traumatic brain injury. [110] This optimal pressure is 
calculated by plotting cerebral autoregulation indices against a range of blood pressures 
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over 4-hour monitoring periods and fitting a U-shaped curve to the data. It is possible to 
retrieve this optimal window at both the population and individual level. The hypothesis 
surrounding this window of cerebral perfusion pressures is that brain arterioles are capable 
of maintaining a constant cerebral blood flow with the largest possible autoregulatory 
reserve at those pressures. At an individual level in the critical care setting, a continuous 
estimation of an ideal cerebral perfusion pressure presents an attractive target for 
hemodynamic management. Indeed, this is reflective of the Cambridge hypothesis 
altogether, which is stated as follows: “Cerebral perfusion pressure (CPP) should be kept 
at the CPP where an individual patient autoregulates most efficiently.” [cppopt.org]  
 
In 2002, Steiner et al. monitored upwards of 10,000 hours of continuous data, including 
mean arterial pressure (MAP), intracranial pressure (ICP), and CPP, in a total of 114 
patients with traumatic brain injury. [110] The pressure reactivity index (PRx) was 
computed as the moving correlation coefficient between time-averaged values of MAP and 
ICP. CPPOPT was defined as the CPP at which PRx achieved its minimum value when 
plotted against CPP. This minimum value corresponds to the index at which autoregulation 
is optimally functioning. In 68 patients (or 60% of the cohort), the authors were able to 
generate a parabolic curve when plotting PRx against CPP; through the generation of this 
curve, they were able to determine a CPPOPT for 60% of their cohort. The primary endpoint 
was 6-month functional outcome on the Glasgow Outcome Scale, which was correlated 
with the difference between actual CPP and CPPOPT. The team found that outcomes 





In 2012, Aries et al. proposed and tested an automated CPPOPT algorithm based on a 
moving 4-hour window, which updated every minute, in another retrospective cohort of 
patients with traumatic brain injury. [16] This time around, the team was able to identify 
CPPOPT for 55% of the total recording period, and they ultimately demonstrated improved 
outcomes in patients who maintained a CPP near the average, automated CPPOPT.  
 
These relatively low yields of CPPOPT generation posed a considerable problem. In other 
studies, this yield dipped as low as 44% of the recording period. [111] Weersink et al. 
identified 6 key factors that were independently associated with the absence of the 
parabolic curve. [112] These factors included absence of slow arterial blood pressure 
waves, higher PRx values, lower amounts of sedative-analgesic drugs, higher vasoactive 
medication doses, no administration of maintenance neuromuscular blockers, and 
decompressive craniectomy operations, all of which associated with the absence of an 
optimal CPP curve.  
 
Depreitere et al. then introduced an innovative and flexible multi-window algorithm for 
CPPOPT calculation. [111] They utilized a low-resolution version of PRx (termed LAx in 
their paper) and calculated a moving weight-averaged value of CPPOPT based on windows 
of different lengths – namely, 2, 4, 6, 8, and 12 hours – instead of a single 4-hour moving 
window. This weighting system favored two criteria: (1) best-fit U-shaped, second-order 
polynomial curves, and (2) lower LAx values. In other words, if the U-curve fit the second-
order polynomial function well, or if the autoregulatory index was very low, the multi-
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window model would preferentially weigh those particular windows, as shown in the 
equation below (Figure 5). This approach yielded a CPPOPT for a staggering 97% over the 
total recording period. Perhaps the authors put their approach best: “Hence, autoregulation 
was investigated in a dynamic way by scanning different time scales to maximally exploit 
and optimize the potential information on cerebrovascular pressure reactivity capacity 







Figure 5. Adapted from Depreitere et al., this figure demonstrates the 
concept underlying the multi-window generation of a weighted CPPOPT. 
The optimum CPP values received a weighting factor based on the goodness 
of fit of their U-shaped curve as well as the lower value of the 
autoregulatory index at CPPOPT. This approach was used in the two Yale 




The evolution of autoregulation-based blood pressure optimization is impressive. With the 
idea of an individualized, optimal cerebral perfusion pressure range in mind, researchers 
have carried out many observational studies in both adult and pediatric settings in an effort 
to personalize hemodynamic care. These studies now stand on the shoulders of Lassen’s 
autoregulatory curve, just now seeing eye-to-eye with society-endorsed guidelines that 
recommend impersonal, imprecise hemodynamic management of patients with 
cerebrovascular disease. Nevertheless, randomized controlled trials are lacking. 
Furthermore, the specialized equipment to monitor and determine optimal pressures is 
expensive and demanding, not universally available, and requires a moderate degree of 
training and interpretation abilities. Of course, ICM+ software licenses (University of 
Cambridge, UK) are required to perform this work, so before widespread distribution of 
these licenses becomes a reality, data regarding effectiveness in randomized trials is 
needed. 
 
The primary goal of said feasibility studies was to trend and define an optimal brain 
perfusion pressure in different patient populations. Secondary goals mostly revolved 
around investigating whether transgressing the limits of this ideal autoregulatory landscape 
correlated with functional outcome. Almost needless to say at this juncture, the main 
hypothesis is that deviation from personalized autoregulatory limits associates with poor 
functional and radiographic outcomes. This hypothesis will be revisited frequently in the 
following chapters. Before transitioning to the studies on which this thesis is based, Table 
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4 below reviews some relevant literature on the published reports attempting to establish 
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Table 4. Summary table of relevant studies on optimum CPP or MAP in 
different patient populations. A handful of the reports went on to examine 
whether deviation from optimal pressures associated with outcome. *This 
2019 study by Rivera-Lara et al. enrolled a heterogenous population of 
acutely comatose patients in their neurocritical care unit. Etiologies 
included intracerebral hemorrhage (32.5%), aneurysmal subarachnoid 
hemorrhage (27.7%), traumatic brain injury (14%), acute ischemic stroke 








A. Subarachnoid hemorrhage 
 
Subarachnoid hemorrhage (SAH) accounts for approximately 1 to 6% of all stroke 
subtypes. [122, 123] There are roughly 30,000 adult cases in the United States per year, 
and 25% die within 24 hours of hemorrhage onset. An additional 40% die within 30 days. 
Moreover, over one-third of survivors sustain major neurologic deficits. While its 
incidence falls well below that of ischemic stroke, the young age of afflicted individuals, 
together with high morbidity and mortality rates, takes a relatively high toll on years of life 
and functionality lost. [124] As an emergent medical and neurosurgical issue, SAH calls 
for a multidisciplinary collaboration to achieve favorable patient outcomes.  
 
The incidence of spontaneous SAH in population-based studies is approximately 9.1 cases 
per 100,000 people annually (95% CI 8.8-9.5) with some regional variation. [125] It is 
thought that 85% of these cases are aneurysmal in etiology, while 10% are the so-called 
perimesencephalic type. [122] The latter non-aneurysmal, spontaneous SAH has a specific 





Figure 6. CT scans of different types of subarachnoid hemorrhage, adapted 
from a 2017 Lancet review by R.L. Macdonald and T.A. Schweizer. [122] 
Panels demonstrate SAH bleeds arising from aneurysms of the right middle 
cerebral artery (A), right internal carotid artery (B), anterior communicating 
artery (C), left middle cerebral artery (D), and right superior cerebellar 
artery (E). Head CT scans of patients with perimesencephalic SAH (F-H, J) 
resemble an aneurysmal SAH from a basilar bifurcation aneurysm (I), 
illustrating that CT or catheter angiography are necessary in all patients with 
this condition. Non-aneurysmal SAH due to cerebral venous thrombosis (K, 
L), trauma (M), pituitary apoplexy (N), and pseudo-subarachnoid 
hemorrhage due to increased intracranial pressure, brain swelling, and 
compression of the basal cisterns (O).  
 
 
The occurrence of SAH peaks between 50 and 60 years of age. [125] It is 1.6 times more 
common in females than in males, but this difference becomes most evident only after the 
fifth decade of life. [125] Risk factors for aneurysm development, aneurysm rupture, and 
subarachnoid hemorrhage are largely similar. These factors include smoking, hypertension, 
excess alcohol intake, and increased cholesterol. [126, 127] Non-modifiable risks comprise 





When an aneurysm bursts, it is an intracranial catastrophe and an unquestionable 
emergency. Blood pushes into the subarachnoid space at arterial pressures until the 
intracranial pressure equalizes across the rupture site and arrests the bleed via thrombosis 
at the aneurysm rupture site. [128] Subtle prodromal events include headache, dizziness, 
orbital pain, diploplia, visual loss, sensory or motor disturbance, ptosis, or dysphasia. These 
symptoms are the results of sentinel leaks, mass effect from aneurysm expansion and 
growth, emboli, or some combination thereof. Classic presentation of SAH itself can 
include the canonical “worst headache of life,” nausea and vomiting, meningeal irritation, 
photophobia, visual changes, focal deficits, sudden loss of consciousness, or seizures 
during the acute phase. Vitals and physical examination findings can include mild to 
moderate blood pressure elevation, temperature elevation or frank fever, tachycardia, 
papilledema, retinal or vitreous hemorrhage (e.g., Terson syndrome resulting from either 
blood tracking through the optic nerve sheath or venous hypertension with rupture of retinal 
veins), as well as global or focal neurologic abnormalities. In fact, the degree of 
encephalopathy at presentation is a major determinant of prognosis. [128]  
 
In approximately 11% of events, subarachnoid hemorrhage can be linked to family history, 
which is defined as two first-degree relatives who have suffered the condition. [129] 
Another 0.3% of cases result from autosomal dominant polycystic kidney disease. 
Interestingly, genome wide association studies (GWAS) have identified 6 definite and 1 
probable loci with common variants associated with brain aneurysms: 4q31.23 (OR 1.22); 
8q11.23–q12.1 (OR 1.28); 9p21.3 (OR 1.31); 10q24.32 (OR 1.29); 12q22 (OR 1.16); 
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13q13.1 (OR 1.20); 18q11.2 (OR 1.22). [130] A recent study examining messenger RNA 
(mRNA) expression in whole blood reported that patients with vasospasm following SAH 
differ from those without vasospasm. [131] Signaling pathways involved in the vasospasm 
group included, among over one thousand others, adrenergic, P2Y, NO, renin-angiotensin, 
thrombin, CCR3, CXCR4, MIF, PKA, PKC, and calcium, thereby supporting a role of both 
coagulation and immunologic systems in those patients suffering from vasospasm. Thus, 
both genome-wide studies on DNA and RNA wield great potential in SAH studies from a 





Figure 7. Adapted from Macdonald’s Lancet review, this figure illustrates 
the pathophysiology of subarachnoid hemorrhage. [122] Hemorrhage into 
various compartments (subarachnoid, intraventricular, intracerebral, 
subdural) can cause brain shift, increased intracranial pressure, herniation, 
Duret brainstem hemorrhages, and death. Systemic effects of SAH include 
cardiac and pulmonary complications, including potentially fatal 
arrhythmias, contractility abnormalities, Takotsubo cardiomyopathy, 
pulmonary edema, and acute respiratory distress syndrome. Brain injury is 
initially due to transient global ischemia and effects of the hemorrhage. 
Delayed neurological complications can ensue, for example, vasospasm and 




The brain injury shown in Figure 7 occurs in two phases, the first of which is termed early 
brain injury. Early injury is caused by transient global ischemia and toxic effects of the 
subarachnoid blood on brain parenchyma. The delayed phase can result in deterioration in 
up to a third of patients about 3 to 14 days after the hemorrhage. [132] Delayed cerebral 
ischemia (DCI), in particular, is the most important complication because no effective 
preventative measure or treatment exists. It is diagnosed when other causes are ruled out 
or deemed insufficient to cause observed neurologic worsening. Cerebral infarction from 
delayed ischemia remains a grave cause of morbidity in patients surviving the initial 
subarachnoid bleed. [133, 134] The pathophysiology of delayed brain infarction is 
postulated to involve a multifactorial constellation of vasospasm, dysfunctional 
autoregulation, microthrombosis, cortical spreading depolarizations and ischemia, as well 
as well capillary transit time heterogeneity. [11, 132, 135, 136] Despite many randomized 
trials, the only pharmacologic agent shown to reduce the risk of DCI and poor outcome is 
the calcium channel blocker nimodipine. Indeed, guidelines recommend oral nimodipine 





Figure 8. Adapted from the New England Journal of Medicine’s 2017 
review on subarachnoid hemorrhage by M.T. Lawton and G.E. Vates. [128] 
Panels A and B display the anatomy of the subarachnoid space and the circle 
of Willis. High pulsatile pressures at arterial branch points lacking tunica 
media promote the formation of saccular aneurysms in susceptible persons. 
Open surgical repair of an aneurysmal bleed (C) involves exposing the 
aneurysm and adjacent normal arteries so that the neurosurgeon can apply 
a titanium clip on the neck of the aneurysm. Endovascular repair (D) 
involves the navigation of an intra-arterial catheter through the circulation 
under fluoroscopic guidance until the catheter tip is in the lumen of the 
aneurysm. Platinum coils are then delivered and packed into the lumen of 
the aneurysm, which slows or prevents blood flow and leads to local 




Management principles in cases of DCI revolve around counteracting reduced oxygen and 
glucose delivery to the brain. [132, 137] Measures include monitoring of the neurologic 
exam, maintenance of euthermia, euvolemia, adequate hemoglobin, glucose, electrolytes 
(especially sodium and magnesium), nutrition, and patient mobilization. These values are 
important because SAH can be associated with natriuresis and decreased body water 
secondary to raised natriuretic peptides, renin activity, aldosterone, catecholamines, and 
arginine vasopressin. [138] However, prophylactic treatments for DCI, such as the 
purported triple-H therapy for vasospasm (hypertension, hypervolemia, hemodilution), as 
well as hypermagnesemia and hypothermia, have not been beneficial in studies and are 
thus no longer officially recommended. [122, 132] Guidelines from the American Heart 
Association nevertheless state that induced hypertension should be carried out in patients 
with DCI unless they have pre-existing high blood pressures. [25] If induced hypertension 
is not possible or ineffective, endovascular pharmacological or mechanical angioplasty is 
recommended.  
 
Another common complication following SAH is hydrocephalus, stemming from 
extravasated blood blocking cerebrospinal fluid absorption through subarachnoid cisterns. 
Parenthetically, recent findings have invoked cerebrospinal hypersecretion as well as 
immunologic pathways in the pathogenesis of hydrocephalus. [139] Regardless of exact 
molecular etiology, hydrocephalus following SAH occurs in a wide range of 15 to 85% of 
cases, though fortunately, most of these cases are not clinically significant. [25] In cases 
causing encephalopathy, management usually calls for placement of an external ventricular 
drain (EVD) to drain cerebrospinal fluid and monitor intracranial pressure. [128] Beyond 
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the brain bleed and the risks of DCI and hydrocephalus, patients with SAH are at risk for 
serious medical and systemic complications. They should be treated in an intensive care 
unit and preferably one that specializes in neurocritical care, as is the usual case for patients 
at Yale-New Haven Hospital. [128] 
 
B. Clinical relevance of autoregulation following subarachnoid hemorrhage 
 
In 1951 at Syracuse Memorial Hospital in New York, Ecker and Riemenschneider first 
described arterial vasospasm in 7 patients with subarachnoid hemorrhage. [140] Given that 
vasospasm’s peak risk window transpires 5-7 days after the hemorrhage, a causal 
relationship between spasm and DCI historically has been assumed. [141] However, the 
fact that some patients with spasm can do well while others deteriorate without spasm casts 
that relationship into apocryphal light. Furthermore, the CONCIOUS-1 and -2 trials of 
2008 and 2011, respectively, showed that clazosentan failed to efficaciously prevent 
ischemia and infarction after SAH, suggesting that arterial narrowing is insufficient to 
explain all the possible mechanisms leading to DCI. The trial acronym stands for 
Clazosentan to Overcome Neurological Ischemia and Infarct Occurring After 
Subarachnoid Hemorrhage. This drug is an endothelin receptor antagonist used to block 
arterial vasoconstriction, and while the drug arm in the trials saw a 36% reduction in the 
need for medical management of vasospasm, both treatment and control groups carried 





Figure 9. Adapted from a 2013 Nature Neurology review on subarachnoid 
hemorrhage and cerebral autoregulation. Panel A shows a digital 
subtraction angiography (DSA) at baseline with an aneurysm arising from 
the left posterior communicating artery. Angiography at day 9 shows the 
embolized aneurysm with severe vasospasm in the left anterior cerebral 
artery and moderate spasm in the left middle cerebral artery. Panel B shows 
perfusion scans performed to assess the hemodynamic consequences of the 
patient’s hemorrhage. There is clearly reduced cerebral blood flow and 
velocity (CBF and CBV, respectively) in the left parietal lobe, with a 
corresponding prolongation of mean transit time and time to peak (MTT 
and TTP, respectively). The findings are in agreement with reversible 
ischemia in the left middle cerebral artery territory but not in the left anterior 
cerebral artery, where more severe vasospasm was seen. Thus, this patient 
illustrates an example of dissociation between cerebral vasospasm and 
perfusion deficits seen in DCI.  
 
 
Experimentally, vasospasm does not diminish cerebral blood flow unless there is a 
secondary insult, such a drop in systemic blood pressure. [144] See Figure 9 for an 
exemplary dissociation between spasm and perfusion deficits on perfusion imaging. 
Together with the CONSCIOUS trial findings, this dual insult concept supports Harper’s 
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dual-control hypothesis from the 1970’s, whereby distal autoregulatory vasodilation 
compensates for proximal vasospasm. [145-147] These compensations have their limits, 
however, and vasodilatory reserve, so to speak, may be exhausted in the setting of severe 
vasospasm. Consequently, when hemodynamic instability occurs, such as a fall in blood 
pressure, cerebral blood flow can drop and lead to ischemia and DCI. Of note, 
autoregulatory impairment as a result of SAH is an insult in its own right, predisposing to 
cerebral infarction irrespective of a dual insult. [11] In 1985 in Denmark, Voldby et al. 
showed that although spasm alone did not predict DCI, the combination of spasm and 
impaired autoregulation led to DCI in a large proportion of enrolled patients (admittedly 
only 38 in total), again supporting Harper’s hypothesis. [148] The authors invoke central 
lactic acidosis secondary to vasospasm as a possible cause of autoregulatory impairment 
and vasoparalysis. Although concrete experimental data are lacking, a plausible idea is that 
autoregulatory and vasodilatory exhaustion translate to shortening of the autoregulatory 
plateau. Conversely, microvascular vasospasm not apparent on angiography could shift the 
plateau towards higher pressures. [11] While it is unclear how exactly the autoregulatory 
curve changes post-SAH, experts assume the curve follows one of three patterns, shown in 
Figure 10.  
 
 
Figure 10. Adapted from Budohoski et al., this figure shows possible 
effects of SAH on the autoregulatory curve, either via a shift to higher 
pressures in the left panel, a narrowing of the autoregulatory plateau in the 
middle, or a complete loss of autoregulatory capacity with passive pressure-
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flow propagation in the right panel. [149] AR, autoregulation; CBF, 
cerebral blood flow; CPP, cerebral perfusion pressure.  
 
 
The majority of studies that have measured dynamic cerebral autoregulation after SAH 
have reported impairment in autoregulatory physiology (Table 5, adapted from the 2013 
Budhoski et al. review and expanded to include more recent studies). The findings 
described in the table ultimately support autoregulation’s clinical import in prognosticating 
and possibly identifying patients at risk for DCI and poor outcome. Additionally, two 
retrospective projects showed that an optimal cerebral perfusion pressure increases post-
SAH. [117, 150] These studies also demonstrated that more time spent above or below that 
optimal pressure is associated with worse outcome, but this finding has not yet been 
replicated in a prospective manner. After SAH, hemodynamic augmentation therapy is 
often implemented to treat vasospasm and prevent DCI, and so it follows a personalized 
cerebral perfusion pressure target, based on autoregulatory physiology, is a reasonable 
strategy. [149] Thus, we set out to monitor autoregulation and personalized limits of 
hemodynamic compensation in a prospective cohort of SAH patients.  
 




blood flow  
measurement 
Pertinent findings  
Giller et al. 
1991 [69] 
25 TCD Absence of autoregulatory hyperemic 
response in all poor-grade patients 
(n=14) but only in approximately 60% 
of favourably graded patients 
Lam et al.  
2000 [151] 
20 TCD Patients with impaired autoregulation 
(n = 5) and vasospasm (n = 6) 
developed DCI; no patients without 
impaired autoregulation (n = 14) had 
DCI  
Rätsep et al. 
2001 [152] 
55 TCD Spasm was associated with DCI only if 
reduced hyperemic response (n=14) 
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was present; in all cases spasm and 
reduced hyperemic response were 
associated with DCI (n=12) and poor 
outcome in 68% 
Lang et al. 2001 
[153] 
12 TCD Testing divided into early (days 1-6) 
and late (day 7-13); 88% of patients 
with intact autoregulation (n=8) had 
good outcomes; impaired 
autoregulation was predictive of 
Glasgow Outcome Scale 1 and 2; late 
phase autoregulation did not have 
predictive value  
Soehle et al. 
2004 [70] 
32 TCD Spasm caused impairments in 
autoregulation, which was more 
affected ipsilateral to spastic vessel, as 
the authors hypothesized 
Tseng et al. 
2005, 2006 
[154-156] 
80 TCD Shorter duration of autoregulatory 
impairment was associated with lower 
incidence of DCI in the pravastatin 
group (n=40)  
Jaeger et al. 
2007, 2012 
[157, 158] 
67 PbtO2  Impaired autoregulation on day 5-6 
post-SAH was an independent 
predictor of DCI (n = 20); impaired 
autoregulation was an independent 
predictor of outcome at 6 months 
(n=56); these were critical studies in 
forming our hypotheses 
Christ et al. 
2007 [159] 
6 TCD Dynamic autoregulation was impaired 
(n=6) compared to healthy controls 
(n=9) 
Tseng et al. 
2007 [160] 
35 TCD, ICP Impaired autoregulation was found 
ipsilateral to aneurysm; hypertonic 
saline improved blood flow but not 
autoregulation (n=35) 
Tseng et al. 
2009 [161] 
80 TCD Shorter duration of autoregulatory 
impairments and decreased incidence 
of severe vasospasm resulted in a 
reduced incidence of new infarctions in 
the EPO group (40% vs. 7.5%, n = 40) 
Bijelinga et al. 
2010 [117] 
25 ICP Intact autoregulation had 87.5% 
positive predictive value for survival 
(n=16); impaired autoregulation in the 
first 48 hours correlated with outcome 
on the modified Rankin scale (n=16) 
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Barth et al. 
2010 [109] 
21 ICP, PbtO2, 
TD-rCBF 
No differences were found in dynamic 
autoregulation between infarction (n=8) 
and no infarction groups (n=13) 
Rasulo et al. 
2011 [162] 
29 ICP  Duration of impaired autoregulation 
was longer in patients with poor 
outcome (n=14); more time spent 
below optimal cerebral perfusion 
pressure was associated with poor 
outcome (n=14) 
Budohoski et 
al. 2012, 2015 
[163-165]  
98 TCD, NIRS Disturbed autoregulation in the first 5 
days post-SAH was an independent 
predictor of DCI; these are key studies 
as well 
Steinmeier et 
al. 1996 [166] 
10 TCD, ICP, 
ABP 
Spontaneous fluctuations of blood 
pressure can be used for assessment of 
autoregulation using continuous 
intracranial pressure signal 
Soehle et al. 
2003 [167] 
NN PbtO2 PbtO2 autoregulation can be harnessed 
to titrate cerebral perfusion pressure 
levels  
Zweifel et al. 
2010 [79] 
27 TCD, NIRS Dynamic autoregulation assessed with 
NIRS correlates with TCD-based 
autoregulatory measures; this was a 
critical study using NIRS to effectively 
track autoregulation after SAH 




Improved correlation of dynamic 
indices of autoregulation after temporal 
synchronization 
Johnson et al. 
2016 [169] 
47 ICP All patients were poor-grade and 
mechanically ventilated; high PRx 
indices associated with low cerebral 
blood flow, as measured by xenon-CT, 
but PRx did not significantly differ 
between patients with or without DCI 
Calviere et al. 
2015 [170] 
30 TCD Neither autoregulatory impairment nor 
vasospasm alone as associated with 
DCI, but the combination of both was 
significantly correlated with DCI, 
supporting Harper’s dual insult 
hypothesis 
Sugimoto et al. 
2016 [171] 
1 ICP Cortical spreading depolarization 
(CSD) and high PRx indices preceded 
development of DCI in a single patient, 
lending support to the idea that both 




Liu et al. 2018 
[172] 
81 NIRS Impaired autoregulation trended toward 
patients with poorer grades of SAH; 
DCI occurred in 39 of 51 (48%) 
patients with impaired autoregulation 
vs. 6 of 30 (7%) patients with intact 
autoregulation 
Al-Jehani et al. 
2018 [173] 
15 TCD Six patients developed vasospasm, and 
5 (83%) of these patients had abnormal 
transient hyperemic response tests on 
initial TCD assessment, performed 24-
48 hours of admission for SAH 
Otite et al. 2014 
[174] 
68 TCD Patients with vasospasm had higher 
transfer function gain, while patients 
with DCI had lower transfer function 
phases; in decision tree modelling, gain 
and phase were strongly predictive of 
vasospasm and DCI 
Ortega-
Gutierrez et al. 
2020 [175] 
8 TCD Lower phase shifts were associated 
with symptomatic vasospasm and DCI, 
with a larger cohort on the way 
Rynkowski et 
al. 2019 [176] 
40 TCD Impaired hyperemic response found in 
19 patients (preserved in n=21) and 
associated with age, infarction, 
APACHE II score, and worse outcome 
Gaasch et al. 
2018 [177] 
43 ICP, ABP, 
PbtO2 
High pressure reactivity indices (PRx) 
but not oxygen reactivity indices 
(ORx), were associated with DCI and 
worse outcome in poor-grade patients 
Abbreviations: DCI, delayed cerebral ischemia; EPO, erythropoietin; ICP, intracranial pressure; NIRS, 
near-infrared spectroscopy; PbtO2, partial pressure of oxygen in brain tissue; PW-MRI, proton 
weighted MRI; SAH, subarachnoid hemorrhage; TCD, transcranial Doppler; TD-rCBF, thermal 
diffusion regional cerebral blood flow; APACHE, acute physiology and chronic health evaluation 
score. 
 
Table 5. Indirect cerebral blood flow methods for measurement of dynamic 
autoregulation in patients with subarachnoid hemorrhage.  
 
 
C. Pilot study on autoregulation monitoring in subarachnoid hemorrhage 
 
The initial SAH bleed triggers inflammatory cascades, vasospasm, microthrombosis, and 
cortical spreading depolarizations, all of which likely contribute to DCI. [14] As reviewed 
in the previous section, the relationship between DCI and any one of these 
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pathophysiologic mechanisms is nonlinear. Instead, these mechanisms likely represent a 
constellation of pathophysiology, rendering patients vulnerable to secondary neurological 
injury. In particular, early impairment of cerebral autoregulation in the setting of 
vasospasm may compromise the brain’s ability to compensate for hemodynamic 
instability, as may occur during an episode of hypotension. [11] Following aneurysmal 
SAH (aSAH), local decline in perfusion pressure from vasospasm and/or global reductions 
of perfusion pressure from hydrocephalus can overwhelm an individual’s autoregulatory 
capacity. Furthermore, the autoregulatory curve can dynamically shift across and within 
individual patients, providing a strong rationale for personalizing blood pressure 
management after aSAH. Nevertheless, the role of cerebral autoregulation in aSAH is not 
fully understood. It has been shown that autoregulatory failure is associated with secondary 
brain injury, possibly leading to cerebral infarctions and poor outcome. [163, 178] One of 
the most commonly used autoregulatory indices is the pressure reactivity index (PRx) 
based on intracranial pressure (ICP); high PRx indices, which reflect dysautoregulation, 
have been associated with morbidity and mortality in aSAH. [177] Like PRx, the non-
invasively acquired NIRS-derived autoregulatory index (TOx) has been linked to DCI and 
poor outcomes in aSAH. [79, 89] Prior work by our group has shown that NIRS monitoring 
can be used to identify BP ranges in individual patients at which autoregulation is optimally 
functioning. Such an autoregulation-derived, personalized BP range may provide a 
favorable physiological environment for the injured brain. [110] This concept is critical in 
the evolving era of personalized medicine, particularly as it remains unclear which patients 




Statement of Purpose 
In this prospective, observational study, we employ a novel methodology to trend 
autoregulatory blood pressure (BP) thresholds in individuals with aneurysmal SAH to 
determine patient-specific blood pressure targets. This approach involves both invasive 
(ICP) and non-invasive (NIRS) continuous measures of cerebral autoregulation and 
optimal BP ranges. Overall, then, the purpose of this study is to define individual BP 
thresholds in patients with SAH and examine how deviating from those thresholds affects 
functional and radiographic outcomes. The primary hypothesis is that deviation from 
personalized autoregulatory limits associates with worse functional and radiographic 
outcomes following SAH. A secondary hypothesis is that invasive and non-invasive 
measures of autoregulatory limits correlate with one another.  
Specific Aim 1: to evaluate the feasibility of our personalized approach (continuous 
pressure-flow autoregulation monitoring) in a prospective, observational pilot 
study in the neuroscience intensive care unit.  
Specific Aim 2:  to correlate invasive (ICP) and non-invasive (NIRS) measures of 
autoregulatory indices and blood pressure limits.  
Specific Aim 3: to assess the impact of deviating from individualized BP targets 
on radiographic and clinical outcomes following aSAH.  
The first aim serves to further establish feasibility at Yale, as several studies listed in the 
prior section have done, while the second and third strive to fill more pressing knowledge 








This was a single-center, prospective cohort study. All patients presenting to the Yale-New 
Haven Hospital Emergency Department with the diagnosis of acute SAH were screened. 
Patents were eligible for enrollment if they were older than 18, were diagnosed with an 
aneurysmal SAH secondary to a ruptured aneurysm, required invasive BP monitoring in 
the Neuroscience ICU, and were able to have optimal BP monitoring initiated within 48 
hours of symptom onset (prior to possible development of vasospasm). An overview of the 
study timeline is provided below in Figure 11.  
 
 
Figure 11. SAH Autoregulation Monitoring: Study Timeline. 
 
Per standard of care, all patients received PO nimodipine. Treatment protocol aimed to 
maintain ICP less than 22 mmHg and cerebral perfusion pressure (CPP) greater than 50 
mmHg. If CPP dropped below 50 mmHg, IV norepinephrine or phenylephrine was 
administered. To treat clinical vasospasm, hypertension with the same vasopressors was 
induced. If unsuccessful, verapamil was administered during angiography; in 29.0% of 




Patients were excluded in the event of a traumatic SAH or other non-aneurysmal condition. 
History of prior SAH or a modified Rankin scale >2 before admission were additional 
exclusion criteria. The institutional review board at the Yale School of Medicine approved 
this study prior to patient recruitment (HIC number 2000022972). All patients or their 
legally authorized representatives provided written informed consent.  
 
Near-Infrared Spectroscopy and Intracranial Pressure 
 
Adhesive NIRS probes were placed on the frontotemporal skull covering cortex typically 
supplied by the middle cerebral artery (Figure 12). These probes connected to the Casmed 
Foresight Elite monitor (Edwards Lifesciences, USA), which measured oxy- and 
deoxyhemoglobin concentrations (Figure 13). The ratio of oxyhemoglobin to total 
hemoglobin (TOI) functions as a cerebral blood flow surrogate and is unaffected by 
extracranial circulation, hemoglobin concentration, cranial thickness, and cerebrospinal 
fluid. [80, 179] Cerebral vasoreactivity mediates autoregulation through local 
vasoconstriction and vasodilation with ensuing fluctuations in cerebral blood flow and 
volume. [95] Autoregulatory function, therefore, can be measured by interrogating changes 
in TOI or ICP in response to MAP fluctuations. Arterial BP was monitored invasively 
through the femoral or radial artery. NIRS, ICP, and BP data were collected continuously 
for up to 1 week following symptom onset, beginning within 48 hours of symptom onset. 
All signals were sampled at a frequency of 200 Hz and recorded using ICM+ software 





Figure 12. Image of NIRS sensor placement. NIRS probes are placed over 
the frontal scalp, above the eyebrows and just below the hairline, curving 
around to the temples. In this manner, the probes sense oxy- and 
deoxyhemoglobin optical densities in the territory most frequently supplied 
by the middle cerebral artery. This placement does not require shaving of 
eyebrows or the hairline, nor does it interfere with routine clinical care. 
 
 
Figure 13. Neuromonitoring setup. The monitoring currently requires one 
NIRS monitoring device and one laptop computer running ICM+ software 
(Cambridge Enterprise, Cambridge, UK) per patient. The laptop computer 
is connected to the patient’s bedside monitor to collect continuous 
physiologic variables including blood pressure. The integrating ICM+ 
software computes the limits of autoregulation from continuous NIRS and 
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BP data. These thresholds can be displayed in real-time on the laptop 
monitor as dynamically updating visual targets for BP management. 
 
ICP was recorded using an external ventricular drain (EVD) in 28 patients. The remaining 
3 individuals in our total cohort of 31 patients did not require EVD placement as part of 
their clinical care and so were not included in ICP-PRx analysis. At Yale, the neurosurgical 
service handles placement of EVDs by tunneling catheters through the scalp (typically via 
Kocher’s point) and into a lateral ventricle; the neurosurgeon subsequently connects the 
catheter to a drainage and pressure monitoring system, which, in turn, is primarily handled 
by specially trained nurses in the Yale-New Haven Hospital Neuro ICU. This connection 
allows for ICP measurements as well as therapeutic drainage and sampling of cerebrospinal 
fluid (CSF). In each patient, the height of the EVD was adjusted such that the pressure 
transducer was anatomically in line with the foramen of Monro, approximately at the level 
of the external auditory meatus (Figure 14).   
 
 
Figure 14. Intracranial pressure monitoring via EVD placement. Image 





In the 28 patients with EVDs, ICP was recorded on ICM+ software at a standard frequency 
of 200 Hz, directly from the pressure transducer illustrated above. (It should be noted that 
NIRS signals and blood pressure data were also recorded at this standard frequency.) Other 
than sampling at a frequency of 200 Hz, the ICP signal did not undergo statistical 
correction.  
 
Regarding artefact in our signal processing, rejecting blood pressure artefact was far more 
commonly encountered than ICP artefact in our cohort. Blood pressure artefact rejection 
occurred via a two-step process: (1) automated ICM+ software detection of pulsatility loss 
in the mean arterial pressure (MAP) waveform, followed by (2) visual inspection of the 
resultant signal in retrospect. An example of blood pressure artefact is provided in an ICM+ 
screenshot below, illustrating a rapid, sharp spike in systolic and diastolic pressure. This 
abrupt increase to a systolic reading of up to 300 mmHg could represent patient movement 
or flushing or kinking of the line. The representative screenshot in Figure 15 shows a lack 
of the MAP signal (red) in the highlighted region, demonstrating that ICM+ automatically 
recognized a lack of pulse pressure pulsatility and, therefore, removed the MAP calculation 
from display. Following this automated detection of MAP artefact, we visually inspected 





Figure 15. Removal of blood pressure artefact. (ICM+ screenshot) 
 
 
Compared to blood pressure, accurately identifying ICP artefact is a more complex task, in 
particular when using an open EVD system. Accordingly, our ICM+ software did not 
automatically recognize artefacts in the ICP waveform as it did for blood pressure in the 
above screenshot. We thus had to rely on retrospective visual inspection of the ICP 
waveform to identify and splice out artefactual signal. Firstly, abrupt drops in the ICP 
recording to zero or rapid increases to non-physiologic values were excluded from further 
analysis. Otherwise, we accepted a degree of noise in this data, while rejecting overtly non-
physiologic readings, which were not frequently encountered in patients’ ICM+ files. In 
only 3 patients, the ICP signal dropped to zero at several times during the recording. These 
junctures were spliced out of the recording period. In several other patients, we edited out 
abrupt, large spikes in the ICP signal that otherwise returned to a normal reading in a matter 
of seconds; this also occurred infrequently in our cohort. Below, in Figure 16, we have 
provided a screenshot example of a sudden spike in the ICP reading that was felt to be non-
physiologic. The remainder of the recording periods were left untouched, as we felt that 
subjectively edited data (without absolute clear guidance of what constitutes artefactual 
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signal in the ICP waveform in subarachnoid hemorrhage in particular) could potentially 
make our approach more challenging from a technical standpoint. Interestingly, various 
“deep-learning” algorithms are currently being developed to aid in the identification and 




Figure 16. An example of ICP artefact that was removed prior to further 
signal processing. (ICM+ screenshot) 
 
  
Regarding EVD status, two recent publications, as well as observations from patients in 
our cohort, led us to including ICP measurements when the EVD was both open and closed. 
These papers will be revisited in the discussion (Part II, Section E). In 2015, Aries et al. 
effectively demonstrated that open and closed EVD systems can be harnessed to calculate 
autoregulatory indices due to the relatively preserved slow fluctuations in the ICP signal. 
[181] As a follow-up study in 2018, Klein et al. described very good agreement of PRx 
indices obtained via intraparenchymal and EVD measurements of ICP. [182] In fact, 3 
patients in our cohort underwent invasive multimodal monitoring with intraparenchymal 
measurements of ICP. These patients also had EVDs to measure ICP. In these patients, the 
ICP waveforms derived from the parenchymal probe and the open EVD system appeared 
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to track each other fairly well. Below, a screenshot of one of said patients is shown (Figure 
17). Times during which the EVD was closed are indicated by arrows; one can appreciate 
that the ICP waveform derived from an open EVD (orange) indeed tracks the ICP 
waveform derived from the parenchyma (white). 
  
 
Figure 17. Mirrored intracranial pressure waveforms derived from an 
open EVD (orange) and the parenchyma (white). (ICM+ screenshot) 
 
 
Therefore, in considering the aforementioned publications together with our observation 
that intraparenchymal and open EVD systems exhibit similar ICP waveforms, we included 
continuous ICP data to derive optimal blood pressure parameters, regardless of EVD status. 
This approach was both more inclusive and analytically practical and resulted in longer 
ICP monitoring periods.  
 
Calculation of Autoregulatory Indices 
 
Arterial BP and cerebral blood flow emerge as dynamic physiologic oscillations, and their 
relationship can be characterized via time-correlation analysis. Indices of autoregulation, 
including the pressure reactivity index (PRx) and tissue oxygenation index (TOx), are 
calculated as rolling correlation coefficients between successively averaged MAP values 
and corresponding ICP or TOI signals, as previously described by Czosnyka et al. [79, 95, 
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183] MAP maintains a negative or near-zero correlation with ICP or TOI when 
autoregulation is functional, indicating pressure-reactive brain blood flow. In contrast, 
MAP positively correlates with ICP or TOI when autoregulation is impaired, whereby 
systemic pressures passively propagate to cerebral vasculature.  
 
Calculation of Optimal Blood Pressure (MAPOPT) 
 
Regarding determination of MAPOPT in individual patients, 5-minute median MAP time 
trends were computed alongside PRx and TOx. MAP values were allotted into bins of 5 
mmHg; corresponding PRx and TOx indices were averaged within these groups. [110] 
Parabolic curve fitting was applied to the binned pressures to illustrate the MAP value with 
the lowest associated PRx or TOx (i.e., the MAP at which autoregulation was most 
preserved). [16] The nadir of this curve reflects MAPOPT. The MAP at which PRx or TOx 
crosses a threshold for impaired autoregulation (set at PRx or TOx=+0.30) yields lower 
and upper limits of autoregulation (LLA, ULA). A continuous time trend of MAPOPT and 
its limits is thus calculated and recorded using a moving 4-hour window that is updated 






Figure 18. Generation of MAPOPT and personalized limits of 
autoregulation. Panel A shows the characteristic parabolic curve that is 
generated when plotting an autoregulatory index against a range of binned 
blood pressures during a 4-hour recording. The vertex of this U-curve is 
located at the point with the lowest autoregulatory index and thus represents 
the optimum blood pressure (MAPOPT). By setting a threshold for impaired 
autoregulation at TOx=+0.30, intersecting MAP values provide estimates 
of lower and upper limits of autoregulation (LLA, ULA). These 
intersections correspond with the inflection points of Lassen’s 
autoregulatory curve, as shown by the dotted vertical lines between Panels 
A and B. In Panel C, a continuous time trend of these limits can be displayed 
in real-time, while superimposing the patient’s actual BP in black, to 
provide clinicians with a dynamically updating BP target. Panel D shows 
another patient’s 12-hour recording, during which the patient’s blood 
pressure frequently oscillated outside personalized limits of autoregulation 





The modified Rankin scale (mRS) was used to assess functional outcome at discharge and 
3 months (see figure below for details on the scale). Unfavorable outcome was defined as 
mRS ≥3. A blinded member of the research team determined 90-day mRS outcomes via 
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telephone interview. Patients were also assessed for shifts across the entire mRS spectrum. 
[184] 
 
Clinical Scores and Radiographic Outcomes 
 
All patients were assigned a Hunt & Hess (HH), modified Fisher (mF), and World 
Federation of Neurologic Surgeons (WFNS) score upon diagnosis of SAH. All patients 
underwent diagnostic and/or therapeutic cerebral angiogram as part of routine clinical care. 
When possible, daily transcranial Dopplers (TCD) were performed during the week after 
aSAH treatment. Further imaging with CT, MRI, or additional angiograms was dependent 
on the treating clinical team and, therefore, patient-specific. Sonographic cerebral 
vasospasm was defined using acceleration of TCD mean blood flow velocity using 
previously defined thresholds, while radiographic vasospasm was defined using CTA, 
MRA, or catheter angiography, as previously delineated.19,34 Clinical vasospasm was noted 
as new focal neurologic signs or deterioration in level of consciousness when other causes 
of worsening had been excluded. Irrespective of vasospasm, delayed cerebral ischemia 
(DCI) was defined as cerebral infarction on CT or MRI associated with neurologic 
worsening that could not otherwise be explained.20,21 All clinical scores and radiographic 
definitions were confirmed in regular adjudication meetings, including two staff 




In each patient, we calculated percent time spent outside the limits of autoregulation 
(%time outside LA). We used - or Fisher’s exact tests, t-tests, and Mann-Whitney U 
tests as appropriate. We used generalized linear models (GLM) to test for associations 
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among %time outside LA and vasospasm, DCI, discharge and 3-month outcome. The GLM 
modeled ordinal logistic regression to assess for shifts across the mRS range. In 
multivariate analysis, we accounted for independent variables that have been associated 
with outcome after aSAH, including age, WFNS, clinical vasospasm, and DCI. Predictive 
performance of %time outside LA for poor outcome was analyzed via area under the 
receiver operating characteristic (ROC) curve. 
 




Thirty-one patients were enrolled (Table 6). Mean NIRS monitoring time was 67.80 
(±50.83) hours. Optimal BP could be calculated for a mean of 89.53 (±6.69) % of the total 
NIRS monitoring period. Patients spent on average 69.13 (±18.93) % of their monitored 
time within LA (Table 7). Among patients with good and poor outcome at discharge and 
90 days, lower and upper limits of autoregulation were not different. BP variability, 
computed as the standard deviation of MAP during the monitoring period, was also not 
significantly different between these groups, though a trend toward greater variability was 
observed in patients with worse discharge outcomes (8.1 vs. 16.6 mmHg, P=0.106). 
Patients with favorable outcome at discharge were younger and experienced angiographic 
vasospasm and DCI less frequently. They also had lower TOx and PRx indices (i.e., more 
intact autoregulation), wider NIRS-derived optimal BP ranges, and spent less time outside 




Table 6. SAH Cohort: Patient Characteristics. 
Total patients 31 
90-day outcomes, n (%) 28 (90.3) 
Sex, F (%) 23 (74.2) 
Age, mean ± SD 57.5 ± 13.4 
Race 
     White 
     Black or African American 
     Hispanic 






Admission WFNS, mean ± SD 2.2 ± 1.2 
Admission HH, mean ± SD 2.7 ± 0.9 
Admission mF, mean ± SD 3.2 ± 1.1 
Admission MAP, mean ± SD 97.6 ± 19.6 
Aneurysm Location, n (%) 
    Acomm 
    Pcomm 
    MCA 
    ICA 
    Pericallosal 
    Basilar tip 
    PICA 
    No definitive lesion on angiogram with 










Medical History*, n (%) 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 
    Diabetes Mellitus (I&II) 
    Cancer 
    Thyroid Disease 
    Migraine 
    Fibromuscular Dysplasia 
    Current Smoker 
    Past Smoker 


















      1 (no alcohol consumption) 
      2 (consumption≤150 grams/week) 




Ictal loss of consciousness, n (%) 13 (41.9) 
Endovascular coiling, n (%) 24 (77.4) 
Surgical clipping, n (%) 3 (9.7) 
EVD placed, n (%) 28 (90.3) 
Intubated, n (%)  28 (90.3) 
Treated for pneumonia, n (%) 13 (41.9) 
Treated for C. difficile, n (%) 1 (3.2) 
Rebleed, n (%) 2 (6.5) 
VP shunt placed, n (%) 1 (3.2) 
Length of stay, mean days ± SD 19.3 ± 11.3 
Early hydrocephalus, n (%) 17 (54.8) 
Vasospasm on TCD, CTA, or MRA, n (%) 15 (48.4) 
Angiographic vasospasm, n (%) 9 (29.0) 
Clinical vasospasm, n (%) 8 (25.8) 
DCI, n (%) 6 (19.4) 
In-hospital mortality, n (%) 5 (16.1) 
90-day mortality, n (%) 5 (19.2) † 
 
Table 6. Patient Characteristics. Baseline demographics are shown. SD: 
standard deviation; F: female; Acomm: anterior communicating artery; 
Pcomm: posterior communicating artery; MCA: middle cerebral artery; 
ICA: internal carotid artery; PICA: posterior inferior cerebellar artery; CT: 
computed tomography; VP: ventriculoperitoneal; CTA: computed 
tomography angiography; MRA: magnetic resonance angiography. 
*Percentages may add to more than 100% due to comorbidity. † Percentage 
indicates the 90-day mortality of the 26 patients who survived post-








Table 7. Neuromonitoring & Hemodynamic Variables. 
 
NIRS Neuromonitoring (n = 31) 
 
Monitoring time (hours) 67.80 ± 50.83 
Percent MAPOPT calculated 89.53 ± 6.69 
Mean ABP (mmHg) 94.25 ± 13.62 
Mean TOx 0.083 ± 0.338 
Mean MAPOPT (mmHg) 93.72 ± 12.57 
Mean LLA (mmHg) 82.16 ± 12.18 
Mean ULA (mmHg) 105.29 ± 11.62 
Mean Range (ULA-LLA, mmHg) 23.13 ± 6.74  
Percent time MAP<LLA 13.02 ± 9.41 
Percent time MAP>ULA 17.82 ± 13.54 
Percent time MAP within LA 69.13 ± 18.93 
Percent time MAP outside LA 30.83 ± 18.87 
\ 
ICP Neuromonitoring (n = 28) 
 
Monitoring time (hours) 83.78 ± 62.26 
Percent MAPOPT calculated 87.80 ± 7.25 
Mean ABP (mmHg) 95.65 ± 13.93 
Mean PRx 0.061 ± 0.401 
Mean MAPOPT (mmHg) 94.99 ± 13.25 
Mean LLA (mmHg) 82.70 ± 12.91 
Mean ULA (mmHg) 106.82 ± 11.70 
Mean Range (ULA-LLA, mmHg) 23.97 ± 5.14 
Percent time MAP<LLA 12.44 ± 7.04 
Percent time MAP>ULA 15.44 ± 9.12 
Percent time MAP within LA 72.12 ± 12.79 
Percent time MAP outside LA 27.88 ± 12.79 
 
Table 7. NIRS and ICP Neuromonitoring & Hemodynamic Variables. 
Neuromonitoring and hemodynamic measures are displayed as means ± 
standard deviations for both NIRS and ICP modalities. NIRS: near-infrared 
spectroscopy; ICP: intracranial pressure; MAPOPT: optimal mean arterial 
pressure; ABP: arterial blood pressure; TOx: tissue oxygenation index; 
PRx: pressure reactivity index; LLA: lower limit of autoregulation; ULA: 








Table 8. Comparison of patients with good (mRS 0-2) and poor (mRS 3-6) 
functional outcome at discharge (n=31).   
 Good Outcome Poor Outcome P VALUE 
Age, median (IQR) 50.0 (40.0-59.5) 63.5 (55.5-73.3) 0.005 
Sex, n (%) 
    Female 











96.0 (76.5-113.5) 94.0 (86.5-104.5) 0.869 
WFNS, median 
(IQR) 
2.0 (1.0-2.0) 2.0 (1.3-3.8) 0.215 
HH, median (IQR) 2.0 (2.0-3.0) 3.0 (2.0-4.0) 0.258 
mF, median (IQR) 3.0 (2.0-4.0) 4.0 (3.0-4.0) 0.082 
Ictal LoC, n (%) 
    Yes 









Vasospasm on TCD, 
CTA, or MRA, n 
(%) 
    Yes 













Vasospasm, n (%) 
    Yes 














    Yes 












DCI, n (%) 
    Yes 












    Yes 












Length of Stay, 
median (IQR) 




TOx, median (IQR) 0.006 (-0.04-0.04) 0.150 (0.06-0.23) 0.002 
LLA, median (IQR) 80.4 (76.4-82.2) 81.6 (74.0-90.5) 0.679 





28.4 (23.6-30.7) 19.6 (15.7-25.4) 0.010 
MAPOPT, median 
(IQR) 
92.8 (86.1-98.7) 91.4 (80.5-100.5) 0.622 
MAP, median (IQR) 94.6 (86.2-99.0) 91.2 (81.8-100.8) 0.514 
MAP Variability, 
median (IQR) 
11.0 (8.9-12.4) 13.4 (10.2-15.6) 0.106 
%time MAP<LLA, 
median (IQR) 
8.1 (3.1-15.5) 16.6 (6.0-24.7) 0.051 
%time MAP>ULA, 
median (IQR) 
9.7 (5.6-11.3) 22.9 (11.6-29.1) 0.002 
%time outside limits 
of autoregulation, 
median (IQR) 
17.9 (13.2-21.8) 40.5 (19.8-54.4) 0.002 
Monitoring Time, 
median (IQR) 




PRx, median (IQR) 0.014 (-0.005-
0.049) 
0.075 (0.04-0.12) 0.001 
LLA, median (IQR) 81.5 (74.8-84.6) 80.9 (72.6-89.6) 0.963 
ULA, median (IQR) 107.7 (95.8-113.6) 107.3 (96.9-118.7) 0.890 
Range, median 
(IQR) 
24.5 (21.3-26-9) 25.0 (18.0-29.4) 0.861 
MAPOPT, median 
(IQR) 
96.3 (84.5-100.0) 90.0 (84.2-105.9) 0.926 
%time MAP<LLA, 
median (IQR) 
6.9 (2.6-13.3) 13.9 (11.0-19.0) 0.029 
%time MAP>ULA, 
median (IQR) 
10.8 (6.2-16.6) 15.8 (11.0-22.3) 0.111 
%time outside limits 
of autoregulation, 
median (IQR) 
22.1 (10.3-29.1) 30.9 (24.4-42.2) 0.015 
Monitoring Time, 
median IQR 
42.7 (16.0-70.0) 93.8 (47.7-172.0) 0.019 
 
Table 8. Comparison of patients with good (mRS 0-2) and poor (mRS 3-6) 
functional outcome at discharge. Utilizing non-parametric statistics (Mann 
Whitney U, chi-squared, or Fisher’s exact test, when appropriate), baseline 
demographic, clinical outcome measures, neuromonitoring as well as 
hemodynamic variables were compared were compared in patients good vs. 
poor outcome at discharge, as determined by a modified Rankin Scale 
(mRS) or 0-2 vs. 3-6, respectively. IQR: interquartile range; WFNS: World 
Federation of Neurologic Surgeons; HH: Hunt & Hess; mF: modified 
Fisher; LoC: loss of consciousness; TCD: transcranial Doppler; CTA: 
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computed tomography angiography; MRA: magnetic resonance 
angiography; DCI: delayed cerebral ischemia; TOx: tissue oxygenation 
index; LLA: lower limit of autoregulation; ULA: upper limit of 
autoregulation; MAPOPT: optimal mean arterial pressure; ICP: intracranial 
pressure; PRx: pressure reactivity index. 
 
 
Table 9. Comparison of patients with good (mRS 0-2) and poor (mRS 3-6) 
functional outcome at 90-day follow-up (n=28).   
 Good Outcome Poor Outcome P VALUE 
Age, median (IQR) 56.0 (45.0-64.0) 67.0 (60.0-74.5) 0.061 
Sex, n (%) 
    Female 











97.5 (83.0-112.8) 94.0 (81.0-104.5) 0.820 
WFNS, median 
(IQR) 
2.0 (1.0-2.0) 2.0 (2.0-3.0) 0.172 
HH, median (IQR) 2.0 (2.0-3.0) 3.0 (2.0-3.5) 0.263 
mF, median (IQR) 3.0 (2.0-4.0) 4.0 (4.0-4.0) 0.048 
Ictal LoC, n (%) 
    Yes 









Vasospasm on TCD, 
CTA, or MRA, n 
(%) 
    Yes 













Vasospasm, n (%) 
    Yes 














    Yes 












DCI, n (%) 
    Yes 












    Yes 












Length of Stay, 
median (IQR) 






TOx, median (IQR) 0.034 (-0.03-0.09) 0.229 (0.10-0.27) 0.002 
LLA, median (IQR) 80.4 (76.2-82.4) 84.7 (76.4-108.9) 0.129 
ULA, median (IQR) 107.9 (97.5-113.3) 100.9 (93.8-125.3) 0.847 
Range, median 
(IQR) 
19.6 (15.7-25.4) 15.8 (13.4-21.1) 0.001 
MAPOPT, median 
(IQR) 
92.8 (86.9-98.4) 91.5 (85.6-119.6) 0.735 
MAP, median (IQR) 93.7 (84.3-98.7) 92.2 (83.1-121.6) 0.847 
MAP Variability, 
median (IQR) 
12.2 (10.3-14.9) 14.0 (9.3-15.0) 0.664 
%time MAP<LLA, 
median (IQR) 
10.0 (3.3-17.5) 24.1 (11.0-25.8) 0.048 
%time MAP>ULA, 
median (IQR) 
9.9 (6.6-17.4) 27.8 (18.4-36.6) 0.004 
%time outside limits 
of autoregulation, 
median (IQR) 
17.9 (14.6-33.3) 52.0 (39.3-65.0) 0.001 
Monitoring time, 
median (IQR) 




PRx, median (IQR) 0.027 (0.007-0.067) 0.075 (0.05-0.14) 0.032 
LLA, median (IQR) 81.6 (74.6-84.2) 80.9 (72.5-101.0) 1.000 
ULA, median (IQR) 108.3 (97.4-113.5) 107.3 (96.9-124.6) 0.934 
Range, median 
(IQR) 
25.0 (17.9-29.4) 24.5 (17.0-30.8) 1.000 
MAPOPT, median 
(IQR) 
96.0 (85.7-100.2) 90.0 (84.7-114.4) 0.890 
%time MAP<LLA, 
median (IQR) 
12.4 (5.1-17.3) 16.4 (11.6-19.7) 0.229 
%time MAP>ULA, 
median (IQR) 
11.8 (8.1-16.4) 17.3 (13.5-34.5) 0.037 
%time outside limits 
of autoregulation, 
median (IQR) 
24.6 (14.7-30.4) 38.5 (29.8-44.8) 0.012 
Monitoring time, 
median (IQR) 
60.1 (40.6-108.2) 93.8 (42.1-172.0) 0.419 
 
Table 9. Comparison of patients with good (mRS 0-2) and poor (mRS 3-6) 
functional outcomes at 90-day follow-up. Utilizing non-parametric statistics 
(Mann Whitney U, chi-squared, or Fisher’s exact test, when appropriate), 
baseline demographic, clinical outcome measures, neuromonitoring as well 
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as hemodynamic variables were compared were compared in patients good 
vs. poor outcome at 90 days, as determined by a modified Rankin Scale 
(mRS) or 0-2 vs. 3-6, respectively. IQR: interquartile range; WFNS: World 
Federation of Neurologic Surgeons; HH: Hunt & Hess; mF: modified 
Fisher; LoC: loss of consciousness; TCD: transcranial Doppler; CTA: 
computed tomography angiography; MRA: magnetic resonance 
angiography; DCI: delayed cerebral ischemia; TOx: tissue oxygenation 
index; LLA: lower limit of autoregulation; ULA: upper limit of 
autoregulation; MAPOPT: optimal mean arterial pressure; ICP: intracranial 
pressure; PRx: pressure reactivity index. 
 
Autoregulatory Indices and Outcome 
 
In univariate analysis, TOx associated significantly with functional outcome at discharge 
(P=0.001, OR 3.0, 95% CI 1.5-5.8) and 90 days (P=0.006, OR 2.5, 95% CI 1.3-4.8). These 
associations held when adjusting separately for age, WFNS, vasospasm, and DCI (Tables 
10 and 11). PRx significantly associated with discharge mRS (P=0.010, OR 6.3, 95% CI 
1.6-25.6) and 90-day mRS (P=0.016, OR 5.6, 95% CI 1.4-22.6). These associations held 
when adjusting separately for age, WFNS, and vasospasm.  
 
Table 10. Predictors of functional outcome at discharge in univariate ordinal 
regression analysis (n = 31). 
VARIABLE P VALUE 
Age 0.016 
Sex 0.647 
Admission MAP 0.525 
Ictal loss of consciousness 0.347 
WFNS 0.007 
Hunt-Hess 0.055 
Modified Fisher 0.082 
Length of stay 0.280 
Early hydrocephalus 0.277 
Radiographic vasospasm (TCD, CTA, or MRA) 0.725 
Angiographic vasospasm 0.023 
Clinical vasospasm 0.028 
Delayed cerebral ischemia 0.004 
Re-bleed 0.167 
Extraventricular drain placed 0.053 
Intubated 0.053 
Treated with surgical clipping 0.252 
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Treating with endovascular coiling 0.834 
Past Medical History 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 
    Diabetes Mellitus (I & II) 
    Cancer 
    Thyroid Disease 
    Migraine 
    Current Smoker 
    Past Smoker 



















Percent time MAPOPT calculated 0.633 
Mean MAPOPT 0.246 
Mean MAP 0.293 
Mean upper limit of autoregulation (ULA) 0.970 
Mean lower limit of autoregulation (LLA) 0.043 
Autoregulatory range (ULA – LLA) 0.001 
Percent time MAP > ULA 0.005 
Percent time MAP < LLA 0.011 
Percent time MAP within limits of autoregulation 0.0004 





Percent time MAPOPT calculated 0.785 
Mean MAPOPT 0.368 
Mean MAP 0.208 
Mean upper limit of autoregulation (ULA) 0.295 
Mean lower limit of autoregulation (LLA) 0.176 
Autoregulatory range (ULA – LLA) 0.243 
Percent time MAP > ULA 0.010 
Percent time MAP < LLA 0.046 
Percent time MAP within limits of autoregulation 0.003 




Table 10. Predictors of functional outcome at discharge in univariate 
ordinal regression analysis. Univariate predictors of worse discharge mRS 
include age, WFNS, angiographic vasospasm, clinical vasospasm, delayed 
cerebral ischemia, and hyperlipidemia. NIRS-derived predictors include 
TOx, LLA, the autoregulatory optimal blood pressure range, %time MAP 
> ULA, %time MAP < LLA, and %time MAP outside autoregulatory limits. 
IPC-derived predictors include PRx, %time MAP > ULA, %time MAP < 
LLA, and %time MAP outside autoregulatory limits.  
 
 
Table 11. Predictors of functional outcome at 90-day follow-up in univariate 
ordinal regression analysis (n = 28). 
VARIABLE P VALUE 
Age 0.007 
Sex 0.648 
Admission MAP 0.785 
Ictal loss of consciousness 0.635 
WFNS 0.071 
Hunt-Hess 0.530 
Modified Fisher 0.088 
Length of stay 0.347 
Early hydrocephalus 0.311 
Radiographic vasospasm (TCD, CTA, or MRA) 0.749 
Angiographic vasospasm 0.058 
Clinical vasospasm 0.126 
Delayed cerebral ischemia 0.011 
Re-bleed 1.000 
Extraventricular drain placed 0.105 
Intubated 0.105 
Treated with surgical clipping 0.920 
Treating with endovascular coiling 0.914 
Past Medical History 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 
    Diabetes Mellitus (I & II) 
    Cancer 
    Thyroid Disease 
    Migraine 
    Current Smoker 
    Past Smoker 





















Percent time MAPOPT calculated 0.883 
Mean MAPOPT 0.577 
Mean MAP 0.621 
Mean upper limit of autoregulation (ULA) 0.658 
Mean lower limit of autoregulation (LLA) 0.125 
Autoregulatory range (ULA – LLA) 0.002 
Percent time MAP > ULA 0.031 
Percent time MAP < LLA 0.006 
Percent time MAP within limits of autoregulation 0.002 





Percent time MAPOPT calculated 0.914 
Mean MAPOPT 0.849 
Mean MAP 0.761 
Mean upper limit of autoregulation (ULA) 0.999 
Mean lower limit of autoregulation (LLA) 0.672 
Autoregulatory range (ULA – LLA) 0.266 
Percent time MAP > ULA 0.028 
Percent time MAP < LLA 0.039 
Percent time MAP within limits of autoregulation 0.004 
Percent time MAP outside limits of autoregulation 0.004 
 
Table 11. Predictors of 90-day functional outcome in univariate ordinal 
regression analysis. Univariate predictors of worse 3-month mRS include 
age, delayed cerebral ischemia, and hyperlipidemia. NIRS-derived 
predictors include TOx, the autoregulatory optimal blood pressure range, 
%time MAP > ULA, %time MAP < LLA, and %time MAP outside 
autoregulatory limits. IPC-derived predictors include PRx, %time MAP > 
ULA, %time MAP < LLA, and %time MAP outside autoregulatory limits.  
 
 
Given the heterogeneity in autoregulation monitoring techniques, we sought to correlate 
our invasive and non-invasive autoregulatory indices. Beyond just the indices, we were 
interested to ascertain whether the NIRS- and ICP-derived personalized blood pressure 
limits correlated well with one another. Non-parametric regression analysis revealed that 
NIRS- and ICP-derived MAPOPT (Spearman 0.92, P<0.0001), LLA (Spearman 0.88, 
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P<0.0001), and ULA (Spearman 0.92, P<0.0001) demonstrated strong correlations with 
one another (Figure 19). To further illustrate agreement, Bland-Altman plots were 
constructed (Figure 20). Overall, the low bias values and relatively narrow 95% confidence 
intervals (dotted lines on the Bland-Altman plots) underscore collinearity between NIRS- 
and ICP-based limits of autoregulation. Moreover, there is apparent scattered variability 




Figure 19. Correlation between ICP- and NIRS-derived limits of 
autoregulation. ICP- and NIRS-derived autoregulatory parameters 
significantly correlated in bivariate non-parametric analysis (Panels A-C). 
Both ICP- and NIRS-derived %time outside LA also correlated with one 
another; the axes in this panel are shown as decimals (Panel D). Best-fit 
lines and corresponding 95% confidence intervals are displayed to illustrate 





Figure 20. Bland-Altman analyses of NIRS- vs. ICP-derived autoregulatory 
parameters. Panels A-D display Bland-Altman plots (difference vs. 
average) for NIRS- vs. ICP-derived LLA, ULA, MAPOPT, and percent time 
MAP spent outside LA. The dotted lines in each plot represent 95% 
confidence intervals. LLA: lower limit of autoregulation; ULA: upper limit 
of autoregulation; MAPOPT: mean arterial pressure; %time MAP outside 
LA: percent time MAP spent outside limits of autoregulation. 
 
 
Limits of Autoregulation and Clinical Outcome 
 
Using ICP-derived optimal blood pressures, %time outside LA was a significant predictor 
of unfavorable outcome at discharge (P=0.003, OR 2.6, 95% CI 1.4-4.9) and 90 days 
(P=0.004, OR 2.8, 95% CI 1.4-5.5) (Figure 21, panels A and B). Every 10% increase in 
time spent outside LA was associated with a 2.8-fold increase in the odds of shifting 
towards a worse outcome on the 90-day mRS. These associations remained significant after 





Figure 21. Percent time MAP spent outside limits of autoregulation 
associates with discharge and 90-day functional outcome following aSAH. 
A&B: Deviating from ICP-derived autoregulatory limits associated with 
discharge and 90-day outcome. C&D: Deviating from NIRS-derived 
autoregulatory limits associated with discharge and 90-day outcome. P-
values shown demonstrate statistical significance in univariate ordinal 
regression. Error bars represent 95% confidence intervals. OR: odds ratio; 
CI: confidence interval. 
 
 
Table 12. Multivariate association between NIRS- and ICP-derived 








TOx, Age 2.6 1.3-5.1 0.006 
TOx, WFNS 2.4 1.2-4.9 0.013 
TOx, Radiographic 
Vasospasm 
3.0 1.5-5.8 0.001 
TOx, Angiographic 
Vasospasm 





3.4 1.7-6.8 0.001 
TOx, DCI 2.7 1.4-5.4 0.005 
%time outside LA, 
Age 
2.2 1.4-3.5 0.001 
%time outside LA, 
WFNS 
2.1 1.3-3.3 0.002 
%time outside LA, 
Radiographic 
Vasospasm 
2.2 1.4-3.5 0.0004 
%time outside LA, 
Angiographic 
Vasospasm 
2.4 1.5-3.9 0.0003 
%time outside LA, 
Clinical Vasospasm 
2.6 1.6-4.3 0.0001 
%time outside LA, 
DCI 




PRx, Age 6.5 1.6-27.1 0.010 
PRx, WFNS 5.2 1.2-22.3 0.028 
PRx, Radiographic 
Vasospasm 
7.2 1.7-30.1 0.007 
PRx, Angiographic 
Vasospasm 
4.9 1.1-20.9 0.034 
PRx, Clinical 
Vasospasm 
4.3 1.1-21.0 0.033 
PRx, DCI 4.2 0.9-19.0 0.064 
%time outside LA, 
Age 
2.6 1.3-4.9 0.004 
%time outside LA, 
WFNS 
2.3 1.2-4.5 0.010 
%time outside LA, 
Radiographic 
Vasospasm 
2.7 1.4-5.1 0.003 
%time outside LA, 
Angiographic 
Vasospasm 
2.3 1.2-4.5 0.012 
%time outside LA, 
Clinical Vasospasm 
2.4 1.2-4.6 0.016 
%time outside LA, 
DCI 
2.4 1.2-4.7 0.011 
 
Table 12. Multivariate association between autoregulatory parameters and 
functional outcome at discharge. This table shows multivariate ordinal 
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regression analysis of autoregulatory indices TOx and PRx as well as %time 
outside autoregulatory limits versus discharge mRS. Separate adjustments 
were performed for age, WFNS, radiographic vasospasm, angiographic 
vasospasm, clinical vasospasm, and DCI due to the small cohort in this pilot 
study. TOx: tissue oxygenation index; PRx: pressure reactivity index; 
WFNS: World Federation of Neurologic Surgeons; DCI: delayed cerebral 
ischemia; MAP: mean arterial pressure; %time outside LA: percentage of 
time that MAP spent outside limits of autoregulation; aOR: adjusted odds 
ratio; CI: confidence interval.  
 
Table 13. Multivariate association between NIRS- and ICP-derived 








TOx, Age 2.0 1.1-3.9 0.033 
TOx, WFNS 2.3 1.1-4.6 0.022 
TOx, Radiographic 
Vasospasm 
2.5 1.3-4.8 0.006 
TOx, Angiographic 
Vasospasm 
2.4 1.3-4.7 0.007 
TOx, Clinical 
Vasospasm 
2.6 1.3-5.0 0.005 
TOx, DCI 2.1 1.1-4.2 0.026 
%time outside LA, 
Age 
2.0 1.3-3.1 0.002 
%time outside LA, 
WFNS 
1.9 1.2-2.9 0.007 
%time outside LA, 
Radiographic 
Vasospasm 
1.9 1.3-3.0 0.002 
%time outside LA, 
Angiographic 
Vasospasm 
1.9 1.3-2.9 0.003 
%time outside LA, 
Clinical Vasospasm 
2.0 1.3-3.0 0.007 
%time outside LA, 
DCI 




PRx, Age 6.2 1.5-25.8 0.013 





6.3 1.5-26.2 0.012 
PRx, Angiographic 
Vasospasm 
4.4 1.0-19.6 0.050 
PRx, Clinical 
Vasospasm 
4.7 1.1-20.8  0.041 
PRx, DCI 3.6 0.7-18.1 0.113 
%time outside LA, 
Age 
3.0 1.5-6.3 0.003 
%time outside LA, 
WFNS 
2.8 1.3-6.1 0.008 
%time outside LA, 
Radiographic 
Vasospasm 
2.9 1.4-5.9 0.003 
%time outside LA, 
Angiographic 
Vasospasm 
2.5 1.2-5.5 0.020 
%time outside LA, 
Clinical Vasospasm 
2.8 1.3-6.1 0.012 
%time outside LA, 
DCI 
2.2 1.0-5.0 0.047 
 
Table 13. Multivariate association between autoregulatory parameters and 
functional outcome at 90-day follow-up. This table shows multivariate 
ordinal regression analysis of autoregulatory indices TOx and PRx as well 
as %time outside autoregulatory limits versus 90-day mRS. Separate 
adjustments were performed for age, WFNS, radiographic vasospasm, 
angiographic vasospasm, clinical vasospasm, and DCI due to the small 
cohort in this pilot study. TOx: tissue oxygenation index; PRx: pressure 
reactivity index; WFNS: World Federation of Neurologic Surgeons; DCI: 
delayed cerebral ischemia; MAP: mean arterial pressure; %time MAP 
outside LA: percentage of time that MAP spent outside limits of 
autoregulation; aOR: adjusted odds ratio; CI: confidence interval.  
 
 
Using NIRS-derived optimal blood pressures, %time outside LA significantly associated 
with poor discharge (P=0.0004, OR 2.2, 95% CI 1.4-3.4) and 90-day outcome (P=0.002, 
OR 1.9, 95% CI 1.3-2.9) (Figure 21, panels C and D). These associations remained 
significant after separate adjustments for the same covariates (Tables 12 and 13). Deviating 
from NIRS-derived autoregulatory limits predicted poor discharge and 90-day outcome 
with high sensitivity and specificity (area under ROC 0.82, 95% CI 0.67-0.98, P=0.003 
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and 0.88, 95% CI 0.76-1.00, P=0.001, respectively; Figure 22). It is interesting to note the 
high degree of similarity across ICP and NIRS modalities with regard to ROC-based 
thresholds for predicting poor outcome at discharge and 90 days. Overall, after rounding 
up to 30% as a conservative threshold, it seems that MAP > 30% outside the limits of 
autoregulation predicts poor outcome with moderately high sensitivity and specificity in 
our cohort.  
 
 
Figure 22. Receiver operating characteristic (ROC) curves of deviating 
from personalized ICP- and NIRS-derived autoregulatory thresholds to 
predict poor functional outcome (mRS 0-2) at discharge and 90 days. Panels 
A and B display ROC curves for ICP-derived percent time MAP spent 
outside autoregulatory limits for discharge and 90-days. Regarding 
thresholds, for Panel A, spending >26.5% MAP outside LA predicted poor 
outcome at discharge with a sensitivity of 64.7% and specificity of 72.7%. 
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For Panel B, spending >29.1% MAP outside LA predicted poor outcome at 
90 days with a sensitivity of 77.8% and a specificity of 68.7%. Panels C and 
D show similar curves for NIRS data. For Panel C, spending >24.7% MAP 
outside LA predicted poor outcome at discharge with a sensitivity of 72.2% 
and a specificity of 84.6%. For Panel D, spending >29.9% MAP outside LA 
predicted poor outcome at 90 days with a sensitivity of 88.9% and a 
specificity of 68.4%. ROC: receiver operating characteristics; MAP: mean 
arterial pressure; %time MAP outside LA: percent time MAP spent outside 
limits of autoregulation; AUC: area under the curve; CI: confidence 
interval.  
 
Three patients underwent treatment for clinical vasospasm during the neuromonitoring 
period; the remaining cohort did not undergo hemodynamic interventions for vasospasm 
during recordings. Given the possible effect of BP interventions on autoregulatory 
function, a sensitivity analysis was performed excluding these patients. After separate 
adjustments for age, WFNS, vasospasm, and DCI, NIRS- and ICP-derived %time outside 
LA remained significantly associated with discharge and 90-day outcomes (Tables 14 and 
15). 
 
Table 14. Multivariate association between NIRS- and ICP-derived 
autoregulatory parameters and functional outcome at discharge, excluding 3 









TOx, Age 2.4 1.2-4.7 0.016 
TOx, WFNS 2.5 1.2-5.1 0.014 
TOx, Radiographic 
Vasospasm 
2.8 1.4-5.5 0.004 
TOx, Angiographic 
Vasospasm 
2.8 1.4-5.7 0.004 
TOx, Clinical 
Vasospasm 
3.1 1.5-6.3 0.002 
TOx, DCI 2.7 1.3-5.4 0.006 
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%time outside LA, 
Age 
2.2 1.4-3.5 0.001 
%time outside LA, 
WFNS 
2.2 1.3-3.6 0.002 
%time outside LA, 
Radiographic 
Vasospasm 
2.3 1.4-3.7 0.001 
%time outside LA, 
Angiographic 
Vasospasm 
2.4 1.4-4.0 0.001 
%time outside LA, 
Clinical Vasospasm 
2.5 1.5-4.3 0.0004 
%time outside LA, 
DCI 




PRx, Age 6.9 1.4-33.0 0.016 
PRx, WFNS 5.9 1.2-29.6 0.031 
PRx, Radiographic 
Vasospasm 
8.7 1.7-44.8 0.010 
PRx, Angiographic 
Vasospasm 
6.5 1.3-32.0 0.022 
PRx, Clinical 
Vasospasm 
6.8 1.4-33.6 0.019 
PRx, DCI 5.8 1.1-29.6 0.036 
%time outside LA, 
Age 
2.0 1.0-4.1 0.046 
%time outside LA, 
WFNS 
2.0 1.0-3.9 0.050 
%time outside LA, 
Radiographic 
Vasospasm 
2.2 1.1-4.4 0.028 
%time outside LA, 
Angiographic 
Vasospasm 
2.0 1.0-4.1 0.042 
%time outside LA, 
Clinical Vasospasm 
2.1 1.1-4.2 0.037 
%time outside LA, 
DCI 
2.1 1.1-4.2 0.035 
 
Table 14. Multivariate association between autoregulatory parameters and 
functional outcome at discharge, excluding 3 patients who underwent 
treatment for clinical vasospasm during the neuromonitoring period. This 
sensitivity analysis shows multivariate ordinal regression analysis of 
autoregulatory indices TOx and PRx as well as %time outside 
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autoregulatory limits versus discharge mRS after excluding 3 patients who 
underwent hemodynamically relevant interventions for clinical vasospasm 
during the neuromonitoring period. Separate adjustments were recursively 
performed for age, WFNS, radiographic vasospasm, angiographic 
vasospasm, clinical vasospasm, and DCI. 
 
 
Table 15. Multivariate association between NIRS- and ICP-derived 
autoregulatory parameters and functional outcome at 90-day follow-up, excluding 









TOx, Age 1.8 0.9-3.6 0.076 
TOx, WFNS 2.7 1.3-5.6 0.009 
TOx, Radiographic 
Vasospasm 
2.3 1.2-4.5 0.015 
TOx, Angiographic 
Vasospasm 
2.3 1.2-4.4 0.015 
TOx, Clinical 
Vasospasm 
2.3 1.2-4.4 0.017 
TOx, DCI 2.4 1.2-4.7 0.014 
%time outside LA, 
Age 
2.0 1.3-3.1 0.003 
%time outside LA, 
WFNS 
2.2 1.3-3.6 0.002 
%time outside LA, 
Radiographic 
Vasospasm 
1.9 1.2-2.9 0.004 
%time outside LA, 
Angiographic 
Vasospasm 
1.9 1.2-2.9 0.004 
%time outside LA, 
Clinical Vasospasm 
1.9 1.2-3.0 0.004 
%time outside LA, 
DCI 




PRx, Age 5.2 3.3-24.0 0.035 





6.2 1.3-29.6 0.022 
PRx, Angiographic 
Vasospasm 
5.7 1.2-28.3 0.033 
PRx, Clinical 
Vasospasm 
10.9 1.7-72.1 0.013 
PRx, DCI 11.3 1.5-83.3 0.017 
%time outside LA, 
Age 
2.2 1.0-4.7 0.043 
%time outside LA, 
WFNS 
2.7 1.2-6.2 0.016 
%time outside LA, 
Radiographic 
Vasospasm 
2.2 1.1-4.7 0.036 
%time outside LA, 
Angiographic 
Vasospasm 
2.4 1.1-5.3 0.032 
%time outside LA, 
Clinical Vasospasm 
3.0 1.3-7.0 0.009 
%time outside LA, 
DCI 
2.5 1.1-5.8 0.028 
 
Table 15. Multivariate association between autoregulatory parameters and 
functional outcome at 90-day follow-up, excluding 3 patients who 
underwent treatment for clinical vasospasm during the neuromonitoring 
period. This sensitivity analysis shows multivariate ordinal regression 
analysis of autoregulatory indices TOx and PRx as well as %time MAP 
spent outside autoregulatory limits versus discharge mRS after excluding 3 
patients who underwent hemodynamically relevant interventions for 
clinical vasospasm during the neuromonitoring period. Separate 
adjustments were recursively performed for age, WFNS, radiographic 
vasospasm, angiographic vasospasm, clinical vasospasm, and DCI.  
 
 
Limits of Autoregulation and Radiographic Outcomes 
 
Six patients suffered from DCI (19.4%). Percent time with MAP outside LA did not 
significantly differ between patients with and without any short-term radiographic 
outcomes (Table 16). Nonetheless, when comparing patients with and without DCI, a trend 





Table 16. Percentage of time MAP spent outside LA in patients with and without 
short-term radiographic and clinical outcomes.  
ICP-derived %time 
outside LA 
Median IQR P VALUE 
Ictal LoC 
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%time outside LA 
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Table 16. Deviation from autoregulatory limits in patients with and without 
short-term radiographic and clinical outcome measures. Using non-
parametric comparisons, %time outside LA did not significantly differ in 
patients with and without ictal loss of consciousness (LoC), early 
hydrocephalus, radiographic vasospasm, angiographic vasospasm, clinical 




Figure 23. Percent time with MAP outside limits of autoregulation (LA) in 
patients with and without delayed cerebral ischemia (DCI). While %time 
with MAP deviating from personalized LA did not significantly differ 
between patients with and without DCI in the Mann Whitney U test, there 
was a readily appreciable trend towards spending more time outside LA in 
patients with DCI in both ICP and NIRS modalities. Error bars represent 





In this pilot feasibility study of 31 patients with aneurysmal SAH (aSAH), we demonstrated 
that continuous estimation of optimal blood pressure and limits of cerebral autoregulation 
is feasible and that deviating from personalized thresholds of autoregulation strongly 
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associates with worse functional outcome, even after adjusting for important prognostic 
covariates. We also showed collinearity between invasively (ICP) and non-invasively 
(NIRS) derived optimal blood pressures and limits of autoregulation, providing support for 
non-invasive measures of autoregulation in patients who may not be candidates for 
invasive procedures.  
 
Studies performed in patients with traumatic brain injury suggest that autoregulatory 
physiology can be harnessed to optimize cerebral perfusion. [185, 186] Although not yet 
proven in prospective studies, retrospective data suggest that this treatment avenue may 
ameliorate outcome after brain injury. Similar findings in patients with aSAH have posited 
that intact autoregulation improves clinical outcomes. [11, 15, 178] Furthermore, 
autoregulatory function was invoked as a secondary endpoint in aSAH clinical trials of 
pravastatin and erythropoietin, both of which reduced the duration of impaired 
autoregulation in tandem with improved discharge outcomes, a decrease of in-hospital 
mortality, and a marked decrease in the incidence of DCI. [154-156] Of note, functional 
improvements were not sustained in 6-month follow-up. These two trials, therefore, 
illustrate that targeting autoregulation is achievable as a therapeutic paradigm, but the 
ultimate benefit of such a strategy remains unclear. 
 
While these studies considered autoregulation in their design, no prospective study has 
examined personalized BP thresholds based on autoregulatory physiology following 
aneurysmal rupture. Optimal BP ranges are unique to individual patient physiology and 
likely influenced by numerous factors. [11, 15, 187] For example, disturbances in 
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autoregulation may be exacerbated when cerebral vessels are unable to adjust for 
vasoconstriction caused by proximal spasm. This dual insult of vasospasm and 
dysfunctional autoregulation may shorten the autoregulatory plateau and render patients 
vulnerable to distal ischemia. In comparison, microvascular spasm may shift the 
autoregulatory curve towards higher pressures. [188, 189] For these reasons, evaluating 
individual patients’ hemodynamics and maintaining BP within autoregulatory limits would 
provide the optimal physiologic environment for the injured brain.  
 
Indeed, in our study, for every 10% increase in time spent outside ICP-derived limits of 
autoregulation, there was a 2.6-fold and 2.8-fold increased likelihood of shifting towards 
worse outcomes on the discharge and 3-month mRS, respectively. Importantly, our 
neuromonitoring was initiated within the first 48 hours of aneurysm rupture, well before 
the vasospasm risk window. In addition, a sensitivity analysis excluding patients who 
underwent treatment for clinical vasospasm revealed persistent significance 
between %time outside LA and functional outcome. These results suggest that deviation 
from optimal BP targets in the early days following aSAH may represent a marker of 
impaired buffering capacity of the cerebral vasculature, potentially helping to identify 
patients who are more susceptible to further damage from hemodynamic instability 
throughout their hospital course. Additionally, patients with worse discharge and 90-day 
outcomes exhibited narrower NIRS-derived optimal BP target ranges consistent with a 
shortening of their autoregulatory plateau. Overall, frequent episodes of hypo- and 
hyperperfusion may manifest as deviation from personalized autoregulation-based 
thresholds, indicating perturbed autoregulatory physiology, which may aid in 
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prognosticating poor outcome.  
 
Although associations between PRx and functional outcome are well established in patients 
with traumatic brain injury, less robust evidence exists for patients with SAH. [177] Mixed 
results have been reported in recent literature, but in general studies have demonstrated a 
strong relationship among high PRx indices, DCI, and poor outcome. [109, 117, 190] Most 
of these studies used measurements of ICP when the EVD is closed, but Aries et al. 
effectively showed that an open EVD system can be used to calculate autoregulatory 
indices due to preserved slow fluctuations in the ICP signal. [181] More recently, Klein et 
al. revealed good agreement of PRx indices obtained via parenchymal and EVD 
measurements of ICP. [182] In our study, then, we included continuous ICP data to derive 
dynamically updating optimal BP parameters regardless of whether the EVD was open. 
This inclusive approach resulted in longer monitoring periods and an increased capacity to 
determine ideal BP in real-time. Ultimately, higher PRx indices correlated with worse 
outcomes in our cohort.  
 
Similar findings have been reported using non-invasive technologies like TCD and NIRS. 
Budohoski et al. found that perturbed autoregulation in the first 5 days after aSAH 
increased the risk of DCI and poor outcome. [163] These authors not only highlighted the 
feasibility of detecting dysautoregulation using NIRS, but they also observed collinearity 
between TCD- and NIRS-based indices of autoregulation. Using these results as a 
launchpad, our study underscores the feasibility of using both invasive and non-invasive 
measures of autoregulation-based optimal BP. Further, we showed that target BP ranges 
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significantly correlated between NIRS and ICP modalities, providing an argument for non-




This study has several limitations, including a small sample size. Given the study’s 
observational design, conclusions about the effect of autoregulation-guided therapy on 
outcome are beyond its scope. While inferences about autoregulatory mechanisms 
underlying DCI are clouded because only 6 patients suffered from this complication, a 
recent 2019 meta-analysis found that autoregulatory impairment likely constitutes an 
accurate predictor of DCI and poor outcome. [191] These authors performed a summary 
receiver operating characteristic of autoregulation disturbances for DCI prediction, 
reporting an area under the curve of 0.87, underlining autoregulation’s clinical import in 
prognostication. In our study, while %time outside LA did not significantly differ in 
patients with and without DCI, there was an appreciable trend towards spending more time 
outside LA in patients with DCI (Figure 21). This interesting observation would align with 
Harper’s dual insult theory, whereby dysautoregulation distal to proximal vasospasm 
results in infarction. [11, 15, 145, 146] In a larger cohort, prospective randomized trials 
using continuous monitoring strategies to calculate optimal BP targets may help to bridge 
this knowledge gap. Lastly, our neuromonitoring was performed early after admission 
before patients were at risk for vasospasm; beginning at this time point was by design, but 
completing some recordings prior to vasospasm was dictated by practical issues, including 
discontinuation of ICP monitoring by the clinical team, recording equipment availability, 
and discharge from the ICU. More longitudinal monitoring is warranted to capture granular 




Conclusion of the subarachnoid hemorrhage neuromonitoring study 
 
Our method of continuous estimation of autoregulatory limits in aSAH patients provides 
an optimal BP range tailored to patients’ individual hemodynamics. This study thus 
constitutes an innovative approach to determine patient-specific dynamic BP targets. 
Findings from this research could ultimately lead to a clinical trial of autoregulation-based 
treatment strategies, including tailored pharmacologic BP augmentation and lowering 






A. Large-vessel occlusion (LVO) ischemic stroke 
 
Globally, the proportion of all strokes attributable to ischemia is 68%, while the incidence 
of hemorrhagic stroke is 32%, which includes intracerebral hemorrhage and subarachnoid 
hemorrhage. In the United States, the proportion of strokes due to ischemia is 87%, which 
stands in contrast to the incidence of other subtypes like intracerebral hemorrhage (10%) 
and subarachnoid hemorrhage (3%). [192, 193] The lifetime risk for adult males and 
females aged over 25 is approximately 25%. [194] On the global stage, stroke is the second 
most common cause of mortality and third most common cause of disability. [195] 
Zooming in on the United States, as of 2017, the annual incidence of new or recurrent 
stroke is approximated to be 795,000 cases. [193] Historically, there has also been an 
increased regional prevalence and higher mortality rate in the southeast, often referred to 
as the “stroke belt” of the US. [196-198] Males exhibit a higher rate of strokes than females 
at younger ages, the incidence being reversed for females over 75 years of age. [193] 
Within the United States alone, disability and long-term complications of stroke cost more 
than $34 billion each year. [193] 
 
According to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria, there 
are five predominant subtypes of ischemic stroke: 1) large-artery atherosclerosis, 2) 
cardioembolism, 3) small-vessel occlusion, 4) stroke of other determined etiology, and 5) 
stroke of undetermined etiology. [199] Regardless of the etiology, the dictum that “time is 
brain!” is autologically critical, as every passing minute of an untreated large-vessel 
occlusion (LVO) leads to the death of two million neurons. It follows that the main 
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principles of acute care in stroke are to achieve timely recanalization and thus reperfusion 
of the ischemic territory, to optimize collateral flow, and to avoid secondary brain injury. 
LVO strokes (occlusions in the basilar artery, internal carotid artery, and middle cerebral 
artery) account for about half of all ischemic events, and they are independently associated 
with poor outcome. [200] These stroke subtypes are often life-changing and debilitating 
from both physical and emotional perspectives. Indeed, over half of patients fail to regain 
functional independence, and almost a quarter pass away 6 months after the stroke. [201] 
 
Regarding recanalization, it is virtually incontrovertible that thrombolysis and 
thrombectomy improve neurologic outcomes. [202] The past few decades have witnessed 
recombinant tissue plasminogen activator’s (tPA) premier role in improving these 
outcomes when administered within 4.5 hours of stroke symptom onset. [203, 204] 
Randomized controlled trials followed by meta-analyses support the therapeutic 
indications of tPA, so long as clinicians ascertain proper eligibility. [205] Necessary 
information to collect includes time last known well, recent surgeries, medical 
comorbidities, blood thinners, NIHSS score, glucose level, blood pressure, and brain 
imagining. While tPA has become standard of care, the treatment has its limitations. In 
addition to the short time window and weighty list of contraindications, pharmacologic 
thrombolysis frequently fails to fully recanalize proximal artery occlusions caused by large 
clots. As stated above, these strokes tend to be some of the most disabling. [202] There is 
now strong evidence that these patients should be considered for endovascular treatment 




Mechanical thrombectomy preceded by intravenous tPA has become standard of care 
treatment in stroke patients with acute ischemia secondary to LVO. [206] This shift 
occurred after 2015, a year that witnessed five randomized trials (MR CLEAN, ESCAPE, 
SWIFT PRIME, REVASCAT, and EXTEND IA) showing efficacy of endovascular 
thrombectomy over standard medical care. [207-211] A subsequent Lancet meta-analysis 
in 2016 [HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular 
Stroke Trials)] included a total of 1,287 patients and demonstrated a significant reduction 
in 90-day disability compared to controls (adjusted common odds ratio 2.49, 95% CI 1.76-
3.53, P<0.0001), though 90-day mortality and risk of parenchymal hematoma and 
symptomatic intracranial hemorrhage did not differ between the two study populations. 
[206] Another landmark trial occurred in 2018 from the DAWN investigators, investigating 
the effect of thrombectomy performed in the 6-24 hour window after the onset of ischemic 
stroke. In this study, 107 patients underwent standard medical care plus thrombectomy (the 
thrombectomy group), while 99 patients received medical care alone (the control group), 
for a total of 206 enrolled patients. The thrombectomy group had to fulfill mismatch criteria 
between severity of clinical deficit and infarct volume on initial brain imaging. The trial 
was halted at 31 months because interim analysis showed significant improvement in the 
thrombectomy group with respect to utility-weighted modified Rankin scale score at 90 
days (5.5 vs. 3.4, posterior probability of superiority >0.999). Further, the rate of functional 
independence at 90 days was 49% in the thrombectomy group as compared to 13% in the 
control group. [212] 
 
Current AHA guidelines recognize that vasopressor therapy may be useful to improve 
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cerebral blood flow “in exceptional cases,” but parameters regarding patient selection and 
blood pressure targets have not been established. [213] Similarly, at this time, post-stroke 
hypertension management does not consider patients’ unique hemodynamic physiology. 
Instead, current guidelines recommend maintaining BP <180/105 mmHg for all patients 
treated with IV t-PA or endovascular therapy to promote perfusion to ischemic territories 
while mitigating potential risks of intracranial hemorrhage, but acknowledge the lack of 
prospective trials to substantiate this position. The following excerpts from the 2018 
Guidelines for the Early Management of Patients With Acute Ischemic Stroke illustrate 
current, endorsed practices for blood pressure (BP) management in ischemic stroke.  
 
Initial BP management 
“Patients who have elevated BP and are otherwise eligible for treatment with IV 
alteplase should have their BP carefully lowered so that their systolic BP is <185 
mmHg and their diastolic BP is <110 mmHg before IV fibrinolytic therapy is 
initiated.” 
 
Post-alteplase BP management 
“BP should be maintained <180/105 mmHg for at least the first 24 hours after IV 
alteplase treatment.” 
 
Post-EVT BP management 
“In patients who undergo mechanical thrombectomy, it is reasonable to maintain 
the BP ≤180/105 mmHg during the first 24 hours after the procedure. In patients 
who undergo mechanical thrombectomy with successful reperfusion, it might be 
reasonable to maintain BP at a level <180/105 mmHg.” 
 
 
The recommendations go on to acknowledge that very little data is available to guide blood 
pressure therapy during and after thrombectomy. [213] Randomized controlled trials are 
not available in this setting. The vast majority of patients enrolled in under 6-hour 
randomized trials received intravenous thrombolytic therapy, and the trial protocols 
stipulated management according to local guidelines with pressures generally under 
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180/105 mmHg for the first 24 hours after the procedure. Importantly, two trial protocols 
provided additional recommendations. The ESCAPE protocol states that systolic blood 
pressure ≥150 mmHg is probably useful in promoting and sustaining adequate collateral 
flow while the artery remains occluded. [208] The protocol further states that controlling 
pressure once reperfusion has been achieved and aiming for a normal pressure is a 
reasonable route for individual patients. Labetalol or metoprolol in low doses are 
recommended for this purpose. Second, the DAWN protocol endorses maintaining systolic 
pressures under 140 mmHg in the first 24 hours for subjects who achieve successful 
reperfusion after thrombectomy. [214] Of note, these blood pressure thresholds from the 
ESCAPE and DAWN protocols will be used as comparisons in our pilot study on 
personalized autoregulatory thresholds in patients with ischemic stroke.   
 
B. Clinical relevance of autoregulation following ischemic stroke 
 
Cerebral autoregulation in acute stroke is critical for the maintenance of stable blood flow 
in the ischemic penumbra and for avoidance of excessive hyperperfusion. [15, 30] 
Unfortunately, there seems to be fairly widespread agreement that stroke is associated with 
impaired autoregulation, even in cases of minor stroke. This impairment may exist 
ipsilateral to the stroke site in a focal fashion, or globally throughout both hemispheres. 
[30] Interestingly, Immink et al. reported dynamic autoregulatory disturbance ipsilateral to 
middle cerebral artery territory strokes but bilaterally in lacunar ischemic strokes. [215] 
This study utilized transfer function analysis (TFA) within the first 72 hours in 10 patients 
with large MCA strokes (mean NIHSS 17), 10 patients with lacunar strokes (mean NIHSS 
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9), and 10 healthy control subjects. Autoregulatory failure was determined via phase shift 
delay. These results were bolstered in more recent analyses by Guo et al. in 2014. This 
paper showed that dynamic autoregulatory markers were impaired ipsilaterally in stroke of 
large artery atherosclerosis but bilaterally in stroke of small artery occlusion. [216] 
Petersen et al. then examined autoregulation on a more longitudinal basis, reporting 
dynamic autoregulatory failure up to 1 week following acute LVO strokes in the MCA. 
More specifically, this investigation showed that phase was lower in the affected cerebral 
hemisphere compared to the contralateral hemisphere (29.6 vs. 42.5 degrees, P=0.004). 
[86] Normalization of autoregulation was observed by the second week after vessel 
occlusion.  
 
Furthermore, in stroke patients with impaired cerebral autoregulation, recovery tends to be 
delayed for up to 3 months, underlining the clinical relevance of autoregulation in stroke 
research. [6, 217] That said, only a handful of studies have looked at functional outcome 
prognostication with respect to autoregulation physiology in stroke. For example, Reinhard 
et al. enrolled 45 patients within 48 hours of LVO MCA ischemic strokes and showed that 
ipsilateral lower phase shifts were related to worse mRS outcomes. [218] In light of the 
prolonged enrollment timeframe, the authors conceded that autoregulatory impairment 
may reflect initial stroke severity, rather than functioning as an independent contributing 
factor to outcome. To help resolve this question, Castro et al. measured autoregulation in 
30 patients with LVO MCA ischemic stroke within just 6 hours of symptom onset. [217] 
This report demonstrated that autoregulatory impairment operated as a statistically 
independent predictor of functional autonomy at the 90-day endpoint (odds ratio 14.0, 95% 
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CI 1.7-74.0, P=0.013). In yet another study, these authors reported that final infarct volume 
is significantly lower in patients with preserved autoregulation in a similar acute window 
after the cerebrovascular accident. [219] In a review summarizing these findings, Castro et 
al. conclude that early measures of cerebral autoregulation likely entail considerable 
impact for the guidance of acute management, prognostication, prevention of secondary 
injury, and ultimate improvement of clinical outcomes. [6] 
 
Hemorrhagic transformation and cerebral edema are feared secondary complications of 
ischemic stroke. Much like vasospasm and delayed cerebral ischemia, prognostic and 
preventative measures are lacking, as are mechanistic underpinnings. Autoregulatory 
physiology has thus been invoked as a biological avenue with possible deterrent and/or 
restorative benefits. In an invasive neuromonitoring study, Dohmen et al. enrolled 15 
patients with MCA ischemic strokes and calculated the cerebral perfusion pressure-oxygen 
reactivity index (COR). [220] They found that COR indices were higher in the 8 patients 
with a malignant course (i.e., massive brain edema formation) compared to the 7 patients 
with a relatively benign course (COR 1.99 vs. 0.68, P<0.05). The study concludes that 
impaired autoregulation appears to play an important role in the development of cerebral 
edema. In an aforementioned study, Castro et al. calculated cerebrovascular resistance, 
coherence, gain, and phase in 46 patients within 24 hours of MCA ischemic stroke. [219] 
At admission, phase was lower (indicative of worse autoregulation status) in patients with 
hemorrhagic transformation (6.6 vs. 45.0 degrees, P=0.023). Also, progression to edema 
was related to lower cerebrovascular resistance values (1.4 vs. 2.3 mmHg/cm/sec, 
P=0.033) and increased blood flow velocities (51 vs. 42 cm/sec, P=0.033) at initial 
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presentation. These lower resistances, the authors submit, reflect paradoxical cerebral 
vasodilation, as resistance is equal to the quotient between mean arterial pressure and mean 
flow velocity (CVR = MAP/MFV). Thus, they argue that breakthrough hyperperfusion and 
microvascular injury may underlie the development of malignant edema and hemorrhagic 
transformation.  
 
Table 17 below displays some of the most relevant literature on autoregulation studies with 
regard to ischemic stroke, together with major findings from each representative study. 
Cumulatively, the evidence for impaired autoregulation following ischemic stroke is 
strong, just as it is for subarachnoid hemorrhage. It follows that the Cambridge hypothesis 
– that an optimum cerebral perfusion pressure exists at a pressure that allows for functional 
cerebral autoregulation – can also be applied to the cerebrovascular hemodynamics of 
stroke pathophysiology.  
 




blood flow  
measurement 




30 TCD Study compared gain and phase in 10 
patients with lacunar ischemic strokes, 10 
patients with MCA ischemic strokes, and 10 
healthy control subjects; autoregulatory 
impairment shown ipsilateral to MCA 








Using invasive probes in patients with MCA 
infarction, authors found early impairment 
of autoregulation in peri-infarct tissue of 
patients who developed malignant edema, 
while autoregulation was preserved in 
patients with more benign courses; 
autoregulation measured via time-







45 TCD Autoregulatory impairment found in 
ipsilateral hemisphere, and low phase as 
well as high Mx indices associated with 
higher NIHSS scores, larger final infarct 
volumes, and worse mRS outcomes 
Guo et al. 
2014 [216] 
41 TCD Phase shifts up to 40 degrees indicative of 
autoregulation impairment were found in 
the ipsilateral hemisphere of large infarcts; 
impairment further shown in patients with 
bilateral lacunar infarcts 
Guo et al. 
2015 [221] 
71 TCD In unilateral MCA stroke patients, dynamic 
autoregulatory failure was shown up to 6 
months post-stroke in both MCA and PCA; 
in lacunar infarction, autoregulatory 




28 TCD Low phase was shown in affected 
hemisphere, and autoregulatory impairment 
was demonstrated up to 7 days after stroke, 
with resolution at 2 weeks 
Castro et al. 
2017 [219] 
46 TCD Autoregulatory impairment with low phase 
shifts shown in affected hemisphere, 
associated with hemorrhage and edema at 
24 hours post-stroke; autoregulatory 
disturbance resolved at 3-month follow-up  
Castro et al. 
2017 [217] 
30 TCD Low phase shifts in ipsilateral hemisphere 
correlated with worse functional outcome at 
90 days post-stroke as well as large infarct 
volume at 24 hours 
Xiong et al. 
2017 [222] 
60 TCD Bilateral autoregulatory impairment shown 
via low phase shifts; also, small vessel 
disease correlated with worse autoregulation 
impairment 
 
Table 17. Cerebral blood flow methods for measurement of dynamic 
autoregulation in patients with ischemic stroke. For further review, Castro et al. and 
Xiong et al. published extensive articles summarizing these studies. [6, 30] 
 
 
C. Pilot study on autoregulation monitoring in ischemic stroke 
 
Endovascular thrombectomy (EVT) has markedly changed the landscape of acute stroke 
therapy and is now considered standard of care for patients with stroke from large-vessel 
intracranial occlusion (LVO). [207, 209-211] However, many patients with LVO stroke 
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have poor functional outcome despite successful EVT. [206] Loss of cerebral 
autoregulation in the acute phase of stroke leaves patients vulnerable to changes in blood 
pressure (BP) with consequent neurologic worsening from hypo- or hyperperfusion. [223] 
Observational studies have found increased rates of hemorrhagic transformation (HT) and 
worse outcomes in patients with higher peak systolic blood pressure (SBP) values or 
hemodynamic variability in the first 24 hours after EVT, suggesting that BP optimization 
may represent a neuroprotective strategy. [224, 225] Current guidelines recommend a BP 
<180/105mmHg for at least 24 hours after EVT but acknowledge the lack of randomized 
trials on this aspect of management. Following reperfusion, lower BP targets may be 
warranted to prevent reperfusion injury and promote penumbral recovery, but optimal 
targets remain unclear, and individual patient factors such as degree of reperfusion, infarct 
size, and hemodynamic status may need to be considered. As a result, there is considerable 
practice variation in post-EVT BP management within the United States. [226]  
 
Prior work has shown that near-infrared spectroscopy (NIRS) monitoring can be used to 
identify a dynamic BP range in individual patients at which autoregulation is optimally 
functioning. [13, 14] Such an autoregulation-derived, personalized BP range may provide 
a favorable physiologic environment for the injured brain following LVO stroke.  
 
Statement of Purpose 
This pilot study seeks to further establish the feasibility of our autoregulation-guided 
algorithm with respect to real-time hemodynamic neuromonitoring in the neuroscience 
intensive care unit. An additional purpose of this study is to examine the impact of 
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exceeding individualized thresholds on radiographic and functional outcomes after 
thrombectomy for LVO ischemic stroke. Our primary hypothesis is that percent time spent 
outside of dynamic blood pressure targets correlates with worse outcome at discharge and 
90-day follow-up. Secondary hypotheses are that percent time above and below the upper 
and lower limits of autoregulation associate with hemorrhagic transformation and infarct 
progression, respectively. Finally, we hypothesize that our autoregulation-based approach 
represents a more personalized alternative to the currently endorsed practice of maintaining 
systolic blood pressures below fixed thresholds after stroke.  
Specific Aim 1: to recapitulate feasibility of autoregulation neuromonitoring and 
derivation of personalized BP limits in patients undergoing EVT for LVO ischemic 
stroke.  
Specific Aim 2: to evaluate the association between deviation from these BP targets 
on radiographic as well as clinical outcomes.  
Specific Aim 3: to compare personalized, autoregulation-guided BP management 
with two commonly used clinical approaches: (1) maintaining BP below a fixed, 
pre-determined value as recommended by current guidelines and (2) stratifying BP 
thresholds based on reperfusion status.  
The first two aims reflect those of the subarachnoid hemorrhage pilot study, while the third 





Study Design and Subjects 
 
This was a single-center, prospective cohort study. All patients presenting to the Yale-New 
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Haven Hospital Emergency Department with the diagnosis of acute anterior circulation 
LVO stroke were screened. Patients ≥18 years were eligible if they underwent EVT, had 
MRI or CT contrast imaging obtained before EVT, and optimal BP monitoring could be 
initiated within 12 hours of procedure completion. History of prior stroke within 3 months 
or a baseline modified Rankin scale (mRS) >3 were exclusion criteria. All stroke 
management decisions including post-procedural BP targets were made by the patients’ 
clinical team in accordance with current American Heart Association (AHA) guidelines. 
[213] Approval for the study was obtained from the institutional review board at the Yale 
School of Medicine (HIC number 1503015485). All patients or their legally authorized 




Similar to the pilot study involving neuromonitoring of patients with subarachnoid 
hemorrhage, the Casmed Foresight Elite monitor was used to monitor oxygenated and 
deoxygenated hemoglobin concentrations in patients with LVO stroke. [80, 179] 
Autoregulatory function was measured by interrogating changes in the NIRS-derived tissue 
oxygenation index in response to arterial BP fluctuations. Arterial BP was monitored 
invasively with a radial or femoral artery catheter. NIRS and BP data were collected 
continuously for up to 48 hours after EVT. All signals were sampled at a frequency of 
200Hz using ICM+ software (Cambridge, UK).  
 
Calculation of autoregulatory indices 
 
As a brief review, continuous recordings of arterial BP and cerebral blood flow 
demonstrate spontaneous oscillations, and their relationship can be characterized using 
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time-correlation analysis. First, the two signals were subjected to a 10-second average 
filter. Then, the tissue oxygenation autoregulatory index (TOx) was computed as a moving 
correlation coefficient between 30 consecutive time-averaged values of mean arterial 
pressure (MAP) and corresponding TOI signals. The index was updated every 10 seconds 
when a new set of hemodynamic variables was added. In this way, a continuous time-trend 
of autoregulatory function was calculated for each patient. [79, 95, 183] MAP has a near-
zero or negative correlation with TOI when autoregulation is intact with pressure-reactive 
cerebral blood flow and volume. In contrast, MAP positively correlates with TOI when 
autoregulation is impaired, signifying that fluctuations in systemic pressure are able to 
transmit passively into the cerebral circulation. 
 
Calculation and continuous trending of optimal blood pressure and limits of 
autoregulation 
 
Regarding determination of optimal mean arterial pressure (MAPOPT), a BP trend was 
recorded alongside TOx in each patient. Using a moving 4-hour window that was updated 
every 1-minute, a continuous time trend of MAPOPT and the limits of autoregulation (LA) 
was recorded, similar to the time trends used in patients with aneurysmal subarachnoid 
hemorrhage (Figure 24). In each patient with LVO ischemic stroke, we calculated the 






Figure 24. Calculating optimal blood pressure and limits of autoregulation. 
Time-correlation analysis allowed for the calculation of a moving Pearson 
correlation coefficient between continuous recordings of mean arterial 
pressure (MAP) and the NIRS-derived tissue oxygenation index (TOI). The 
resultant tissue oxygenation autoregulatory index (TOx), derived as said 
rolling coefficient between 30 successive, time-averaged values of MAP 
and TOI, can then be displayed as a time series alongside MAP and TOI 
(not shown). Limits of autoregulation (Panel A) were subsequently 
calculated by dividing MAP values into groups of 5mmHg and plotting 
them against corresponding TOx indices, resulting in a characteristic U-
shaped curve. After superimposing a threshold for impaired autoregulation 
(TOx=+0.30), intersecting MAP values provide estimates of the lower and 
upper limits of autoregulation (LLA, ULA), which correspond to the 
inflection points of the classic autoregulatory curve (red line, CBF=cerebral 
blood flow). In Panel C, a continuous time trend of optimal MAP (red line), 
ULA and LLA (red lines surrounding MAPOPT) can be calculated in this 
manner, while superimposing the patient’s real-time MAP (black line). This 
trend provides clinicians with a dynamically updating, visual blood pressure 
target, and areas of relative hypo- or hyperperfusion can be readily 
interpreted at the bedside (see highlighted red areas between patient’s MAP 
and ULA, signifying periods in which the patient exceeded personalized 
limits of autoregulation). This approach can be compared to the current 
approach to systolic blood pressure (SBP) management, whereby clinicians 
titrate SBP below certain thresholds, disregarding individual factors like 
cerebral autoregulation. Panels C and D display the same patient’s blood 
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pressure recording over a 12-hour period; while SBP oscillated below fixed 
systolic targets of 180mmHg, as currently recommended, it is clear that the 
patient’s MAP frequently exceeded personalized targets, potentially 
rendering an injured brain vulnerable to further damage from relative 
hyperperfusion. In contrast, the patient’s SBP was above the SBP threshold 
of 140mmHg during periods where his MAP was within limits of 
autoregulation and further lowering of BP in that setting may result in 
cerebral hypoperfusion.  
 
 
Static Blood Pressure Thresholds 
 
To compare our model of identifying optimal BP targets with a more pragmatic approach, 
we chose several fixed SBP thresholds, including thresholds commonly used in clinical 
practice, in recent EVT trials, [211, 212] or those recommended by current guidelines. 
[213] We calculated the percent time that SBP exceeded fixed thresholds of 140 mmHg, 
160 mmHg, and 180 mmHg. We applied these thresholds either to the entire group of 
patients, or to groups stratified by reperfusion status, with lower BP for patients who 
achieved successful reperfusion (TICI 2b or 3). For the latter tiered approach, we applied 
BP parameters of <140 mmHg vs. <185 mmHg and <160 mmHg vs. <185 mmHg that were 
used in the DAWN (DWI or CTP Assessment with Clinical Mismatch in the Triage of 
Wake Up and Late Presenting Strokes Undergoing Neurointervention) and REVASCAT 
(Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment 
of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within 




Functional outcome was measured using the mRS at discharge and 90 days. Endpoints 
were determined via telephone interview at 3 months by a research associate blinded to 






All patients underwent repeat CT imaging at 24 hours as part of routine care. HT has been 
associated with poor outcome after EVT. [227, 228] We classified HT using the European 
Cooperative Acute Stroke Study (ECASS) scale and divided patients into three groups: no 
HT, hemorrhagic infarction (HI), and parenchymal hematoma (PH). [228] HT was further 
classified as symptomatic (sICH) if the hemorrhage was associated with clinical worsening 
or an increase of ≥4 points on the NIHSS, as commonly defined. [207, 210, 211] 
Additionally, since 2016, the clinical protocol for EVT pre-evaluation has also included 
CT perfusion imaging, which was processed with the use of fully automated software 
(RAPID, iSchemaView, Menlo Park, CA). Irreversibly injured brain (ischemic core) was 
diagnosed if the relative cerebral blood flow was <30% of that in normal tissue. In addition, 
all patients underwent magnetic resonance imaging as part of their routine clinical workup 
at 24 hours postintervention. Final infarct volumes were measured using RAPID software 
and defined as pixels with apparent diffusion coefficient values below 680×10−6 mm2/s. 
Since automated volume computation based on apparent diffusion coefficient threshold 
values can become inaccurate in the setting of significant hemorrhagic transformation, 
manual tracings were employed in these instances to calculate the final infarct volume 
(Analyze 11.0, AnalyzeDirect, Overland Park, KS). Infarct growth was calculated as the 
difference between pre-EVT infarct core and final infarct volume on follow-up imaging. 
 
Statistical analysis  
 
Baseline characteristics were summarized by means and standard deviations (SD) for 
normally distributed continuous variables, medians and interquartile ranges (IQR) for 
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skewed continuous variables, and numbers (%) for categorical variables. We dichotomized 
mRS scores into favorable (mRS 0-2) and unfavorable (mRS ≥3) outcomes. We used - 
or Fisher’s exact tests, t- or Mann-Whitney U tests, and Kruskal-Wallis tests as appropriate 
for comparisons between groups. We performed ordinal, binary logistic, or linear 
regression modeling, as appropriate. We accounted for common confounders and known 
predictors of outcome after LVO stroke, including age, admission NIHSS, Alberta Stroke 
Program Early CT (ASPECT) score, and thrombolysis in cerebral infarction (TICI) score. 
All statistics were computed using SPSS (Version 24, IBM Corp). Statistical significance 
was set at P<.05 (two-tailed) for all analyses, including the primary hypothesis that percent 
time above fixed thresholds or outside of dynamic BP targets correlate with functional 
outcome.  
 





Ninety patients were initially enrolled in the study (Table 18). Twelve patients were 
excluded from analysis due to insufficient monitoring time (n=6), poor signal quality (n=5), 
and early withdrawal of care (n=1). The mean monitoring time was 28.0±18.4 hours. 
Optimal BP and LA could be calculated for mean of 83.2±14.7% of the total monitoring 
period. Patients spent a mean of 65.7±22.9% of their monitored time within personalized 
limits of autoregulation, 16.5±13.4% above their upper limit, and 17.9±15.2% below their 




Table 18. Patient Characteristics 
Total patients 90 
90-day outcomes, n (%) 78 (86.7) 
Sex, F (%) 42 (46.7) 
Age, mean ± SD 71.6 ± 16.2 
Race 
     White 
     Black or African American 
     Hispanic 






Admission NIHSS, mean ± SD 13.9 ± 5.7 
Admission ASPECTS, mean ± SD 8.8 ± 1.6 
Admission MAP, mean ± SD 107.3 ± 17.2 
Admission Glucose, mean ± SD 137.3 ± 68.3 
Affected Side, Left (%) 45 (50.0) 
Occlusion on Angiography*, n (%) 
    ICA 
    tICA 
    ACA 
    ACA+MCA 
    M1 MCA 








Medical History*, n (%) 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 
    Diabetes Mellitus (I & II) 
    Ischemic Stroke 
    Cancer 
    Thyroid Disease 
    Current Smoker 














Treated with tPA, n (%) 38 (42.2) 
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Mean time to reperfusion (minutes), mean ± SD 575.98 ± 407.7 
Successful recanalization, n (%)  67 (74.4) 
TICI Score, n (%) 
     0 
     1 
     2a 
     2b 







Hemorrhagic transformation, n (%) 
      HI I 
      HI II 
      PH I 
      PH II 







Symptomatic hemorrhagic transformation, n (%) 8 (8.9) 
Cerebral edema, n (%) 10 (11.1) 
In-hospital mortality, n (%) 14 (15.6) 
90-day mortality, n (%) 23 (25.6) 
 
Table 18. Demographic and baseline characteristics. Data are mean (SD) 
and n (%). SD, standard deviation; F, female; NIHSS = National Institutes 
of Health Stroke Scale; ASPECTS = Alberta Stroke Program Early CT 
Score; MAP, mean arterial pressure; ICA, internal carotid artery; tICA, 
terminal internal carotid artery; ACA, anterior cerebral artery; MCA, 
middle cerebral artery; tPA, alteplase; TICI = thrombolysis in cerebral 
infarction score; HI = hemorrhagic infarction, PH = parenchymal 




Table 19. Neuromonitoring and Hemodynamic Variables  
Mean monitoring time (hours), mean ± SD 28.0 ± 18.4 
Patients with sufficient monitoring (> 6 hours) 90 patients 
Optimization curve calculated successfully, mean ± SD 83.2 ± 14.7% 
Patients with sufficient monitoring and discharge outcomes, n (%) 90 (100) 
Patients with sufficient monitoring and 90-day outcomes, n (%) 78 (86.7) 
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Mean MAP (mmHg), mean ± SD  93.7 ± 12.1 
Mean upper limit of autoregulation (mmHg), mean ± SD 104.7 ± 11.5 
Mean lower limit of autoregulation (mmHg), mean ± SD 83.7 ± 12.1 
Mean MAPOPT (mmHg), mean ± SD 93.3 ± 12.0 
Percent time SBP above 120 mmHg, mean ± SD 81.8 ± 24.1% 
Percent time SBP above 130 mmHg, mean ± SD 68.7 ± 30.9% 
Percent time SBP above 140 mmHg, mean ± SD 54.9 ± 33.5% 
Percent time SBP above 160 mmHg, mean ± SD 23.7 ± 26.8% 
Percent time SBP above 180 mmHg (AHA guideline), mean ± SD 6.0 ± 14.7% 
Percent time SBP above DAWN thresholds, mean ± SD 41.0 ± 35.2% 
Percent time SBP above REVASCAT thresholds, mean ± SD 17.9 ± 24.1% 
Percent time MAP within limits of autoregulation, mean ± SD 65.7 ± 22.9% 
Percent time MAP above the upper limit of autoregulation, mean ± SD 16.5 ± 13.4% 
Percent time MAP below the lower limit of autoregulation, mean ± SD 17.9 ± 15.2% 
 
Table 19. Neuromonitoring and hemodynamic variables. Data are mean 
(SD) and n (%). SD, standard deviation.  
 
 
Blood pressure, limits of autoregulation, and functional outcome 
 
Twenty-seven (30%) patients achieved functional independence (mRS 0-2) at 3 months. 
Patients with good outcome were younger (63 vs. 77 years, P<0.001) and had lower 
admission NIHSS scores (12 vs. 16, P=0.001). They also had lower rates of HT (25.9% vs. 
58.0%, P=0.007), smaller infarct volumes (35.4 vs. 106.5 mL, P<0.001), and less infarct 
progression (32.8 vs. 103.2 mL, P=0.001). The average percent time spent within 
autoregulatory limits among patients with favorable outcomes was 79.0±12.4% compared 





Table 20. Univariate comparisons between groups of good (mRS 0-2) and poor 
(mRS 3-6) functional outcome to determine predictors of outcome at 90-days 





Age, mean ± SD 63.1 (17.3) 77.1 (13.1) <0.001 
Sex, F (%) 10 (37.0) 27 (52.9) 0.181 
Admission NIHSS, mean ± SD 11.6 (5.6) 15.6 (5.5) 0.004 
Admission ASPECTS, mean ± SD 9.0 (1.5) 8.8 (1.4) 0.445 
Admission MAP, mean ± SD 106.5 (18.0) 107.8 (16.9) 0.761 
Admission Glucose, mean ± SD 125.3 (33.1) 148.0 (85.5) 0.021 
Affected Side, n (%) 
     Left 









Medical History, n (%) 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 
    Diabetes Mellitus (I & II) 
    Ischemic Stroke 
    Cancer 
    Thyroid Disease 
    Current Smoker 








































Mean monitoring time (hours), mean 
± SD 
25.4 (14.4) 30.0 (20.5) 0.221 
Percent time MAP within limits of 
autoregulation, mean ± SD 
79.0 (12.4) 60.0 (24.1) <0.001 
Percent time MAP above the upper 
limit of autoregulation, mean ± SD 
8.2 (5.3) 19.5 (12.6) <0.001 
Percent time MAP below the lower 
limit of autoregulation, mean ± SD 
12.9 (12.1) 20.8 (16.8) 0.026 
Mean MAP (mmHg), mean ± SD  91.7 (14.3) 93.9 (10.6) 0.445 
Mean upper limit of autoregulation 
(mmHg), mean ± SD 
104.6 (14.3) 104.2 (10.1) 0.801 
Mean lower limit of autoregulation 
(mmHg), mean ± SD 
80.3 (12.3) 84.8 (11.2) 0.086 
Mean MAPOPT (mmHg), mean ± SD 91.5 (14.0) 93.9 (10.5) 0.384 
Treated with tPA, n (%) 13 (48.1) 20 (39.2) 0.447 
Time to reperfusion (minutes), mean ± 
SD 
475.0 (271.9) 640.6 (474.7) 0.103 
Successful recanalization, n (%)  23 (85.2) 36 (70.6) 0.178 
TICI Score, n (%) 









     1 
     2a 
     2b 










Hemorrhagic transformation, n (%) 
      HT I 
      HT II 
      PH I 
      PH II 


















transformation, n (%) 
1 (3.7) 6 (11.8) 0.411 
Cerebral edema, n (%) 1 (3.7) 8 (15.7) 0.152 
Final infarct volume (mL), mean ± SD 35.4 (46.3) 106.5 (92.8) <0.001 
Infarct progression (mL), mean ± SD 32.8 (44.7) 103.2 (87.9) 0.001 
 
Table 20. Univariate analysis of predictors of good functional outcome 
90 days after endovascular therapy for large vessel occlusion stroke. 
Significant differences between groups were determined using T-tests and 
chi-squared analysis for normally distributed data, while Mann-Whitney U 
tests were used for non-parametric variables. Fisher’s exact test was 
employed for cross tables containing fewer than five patients.  
 
 
After adjusting for age, admission NIHSS, ASPECT score, and degree of reperfusion, 
%time>ULA was independently associated with higher (worse) mRS scores at discharge 
(adjusted OR per 10% time>ULA 1.53, 95% CI 1.13-2.07, P=0.006) and 90 days (adjusted 
OR per 10% time>ULA 1.91, 95% CI 1.29-2.84, P=0.001; Table 21 and Figure 25A&B). 
While we observed no significant association between %time<LLA and functional 
outcome, there was a general trend toward decreasing time within limits of autoregulation 











Table 21. Association of hemodynamic variables with functional outcome 
Likelihood of a shift towards worse outcome on discharge mRS 




1.5 1.1-2.1 0.005 1.53 1.13-2.07 0.006 
%time SBP>160, 
per 10-percent 
1.1 1.0-1.3 0.148 1.1 0.9-1.3 0.272 
%time SBP>180, 
per 10-percent 




1.0 0.9-1.1 0.988 0.9 0.9-1.2 0.699 
Likelihood of a shift towards worse outcome on 90-day mRS 




1.84 1.3-2.7 0.002 1.91 1.29-2.84 0.001 
%time SBP>160, 
per 10-percent 
1.2 1.0-1.4 0.050 1.1 0.9-1.3 0.239 
%time SBP>180, 
per 10-percent 




1.1 1.0-1.2 0.311 1.0 0.9-1.2 0.549 
 
Table 21. Association of hemodynamic variables with functional outcome. 
aOR, adjusted odd ratio (adjusted for age, admission NIHSS, ASPECT 
score, and TICI score); OR, odds ratio; MAP, mean arterial pressure; mRS, 
modified Rankin scale; ULA, upper limit of autoregulation; LA, limits of 
autoregulation; LLA, lower limit of autoregulation; CI, confidence interval. 
 
 
Exceeding the upper limit of autoregulation and risk of hemorrhagic transformation 
 
HT was seen in 39 (43.3%) of patients and was overall associated with poor outcome. We 
observed a progressive increase in %time>ULA with worsening grades of HT (11.4% for 
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no HT, 13.5% for HI1&2, and 20.9% for PH1&2; P=0.03; Figure 23C). Patients who 
developed sICH appeared to spend more time above the ULA when compared to patients 
without sICH (11.9% vs. 24.6%, P=0.1; Figure 25C).  
 
 
Figure 25. Associations of individualized limits of autoregulation with 
functional outcome at discharge and 90 days, hemorrhagic transformation, 
and infarct volume. Percent time spent above ULA was plotted as medians 
with 95% confidence intervals per each mRS score at discharge and 90 days 
(Panel A&B). Panel C shows the %time MAP>ULA among degrees of 
hemorrhagic transformation (HT) and symptomatic intracerebral 
hemorrhage (sICH). Final infarct volume did not correlate with percent time 
spent below LLA in the subgroup of patients who did not achieve 
reperfusion (TICI 0, 1 or 2a), nor in those patients who did achieve 








Blood pressure below the lower limit of autoregulation and infarct progression 
 
In the subgroup of patients with baseline CT perfusion imaging, we calculated infarct 
progression by measuring infarct volume on CT or MRI at 36-48 hours and subtracting the 
core infarct on admission. In this subgroup, we observed a significant bivariate correlation 
between infarct progression and %time<LLA (Spearman’s coefficient 0.31, P=0.016; 
Figure 25D).  
 
Association between SBP above fixed thresholds with HT and functional outcome 
 
Time spent above fixed SBP thresholds gradually decreased for increasing BP levels. On 
average patients spent 81.8+24.1% of their monitoring time above 120 mmHg compared 
to only 6.0+14.7% above 180 mmHg (Table 19). Using the tiered approach with SBP 
targets stratified by reperfusion status, patients spent on average 40.3%+35.4% and 
17.2%+23.7% of the monitoring time above respective thresholds used in the DAWN and 
REVASCAT trials (Table 19). There was no significant association between time spent 
above any of the fixed SBP thresholds and HT, sICH or functional outcome (Tables 22-
24). 
 
Table 22. Association of percent time spent above SBP thresholds with 
outcome 
Likelihood of a shift towards worse outcome on discharge mRS 
Variables OR 95% CI p Value aOR 95% CI p Value 
%time SBP>140, 
per 10-percent 
1.1 1.0-1.2 0.084 1.1 1.0-1.2 0.213 
%time SBP>160, 
per 10-percent 
1.1 1.0-1.3 0.148 1.1 0.9-1.3 0.272 
%time SBP>180, 
per 10-percent 










1.0 0.9-1.2 0.709 1.0 0.9-1.2 0.776 
%time MAP 










0.082 1.13 0.88-1.46 0.34 
Likelihood of a shift towards worse outcome on 90-day mRS 
Variables OR 95% CI p Value aOR 95% CI p Value 
%time SBP>140, 
per 10-percent 
1.2 1.1-1.4 0.003 1.2 1.0-1.3 0.053 
%time SBP>160, 
per 10-percent 
1.2 1.0-1.4 0.050 1.1 0.9-1.3 0.239 
%time SBP>180, 
per 10-percent 








1.1 0.9-1.3 0.395 1.0 0.8-1.2 0.856 
%time MAP 










0.11 1.16 0.89-1.53 0.275 
 
Table 22. Association of percent time spent above SBP thresholds of 120, 
140, 160, and 180 mmHg with functional outcome at discharge and 90-days. 
The DAWN, and REVASCAT trials stratified blood pressure management 
by recanalization status. In DAWN, systolic blood pressure was maintained 
below 140 mmHg in patients who achieved successful recanalization (TICI 
2b or 3). In REVASCAT, systolic blood pressure was maintained below 
160 mmHg in patients with successful recanalization. In both trials, systolic 
blood pressure was maintained below 185 mmHg in patients with 
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unsuccessful recanalization (TICI 0, 1, or 2a). aOR, adjusted odd ratio 
(adjusted for age, admission NIHSS, ASPECT score, and TICI score); OR, 
odds ratio; SBP, systolic blood pressure; mRS, modified Rankin scale; CI, 
confidence interval; DAWN, DWI or CTP Assessment with Clinical 
Mismatch in the Triage of Wake-Up and Late Presenting Strokes 
Undergoing Neurointervention with Trevo; REVASCAT, Randomized 
Trial of Revascularization with Solitaire FR Device versus Best Medical 
Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large 
Vessel Occlusion Presenting within Eight Hours of Symptom Onset.  
 
 
Table 23. Comparison of percent time spent above SBP thresholds in patients 
with and without hemorrhagic transformation 
 No HT HT p Value 
%time SBP>120 mmHg 92.9 (75.0-99.2) 90.2 (74.0-99.0) 0.967 
%time SBP>140 mmHg 64.0 (18.6-83.9) 57.8 (33.0-86.8) 0.525 
%time SBP>160 mmHg 12.4 (1.3-33.2) 15.8 (3.2-46.3) 0.478 
%time SBP>180 mmHg 0.62 (0.18-4.1) 0.86 (0.35-5.3) 0.255 
%time SBP>DAWN 
threshold 




5.8 (0.42-22.7) 9.3 (1.1-26.2) 0.257 
 
Table 23. Mann Whitney-U comparisons of percent time spent above SBP 
thresholds in patients with and without hemorrhagic transformation. HT, 
hemorrhagic transformation; SBP, systolic blood pressure. Data 
summarized by median and interquartile range.  
 
 
Table 24. Comparison of percent time spent above SBP thresholds in patients 
with and without symptomatic intracerebral hemorrhage 
 No sICH sICH p Value 
%time SBP>120 mmHg 93.1 (75.1-99.3) 79.1 (67.2-84.7) 0.037† 
%time SBP>140 mmHg 64.4 (28.0-86.0) 37.1 (8.5-54.7) 0.079 
%time SBP>160 mmHg 15.8 (2.1-45.4) 5.4 (1.7-18.3) 0.178 
%time SBP>180 mmHg 0.74 (0.16-5.7) 0.68 (0.44-1.4) 0.734 
%time SBP>DAWN 
threshold 




7.6 (0.77-26.6) 3.5 (0.34-18.3) 0.391 
 
Table 24. Mann Whitney-U comparisons of percent time spent above SBP 
thresholds in patients with and without hemorrhagic transformation or 
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symptomatic intracerebral hemorrhage. sICH, symptomatic intracerebral 
hemorrhage; SBP, systolic blood pressure. Data summarized by median and 
interquartile range. † While this p-value dips below 0.05, the significant 
difference to which it pertains does not negate our primary hypothesis. In 
other words, the p-value demonstrates that patients with sICH spent 
significantly less time above 120 mmHg compared to patients without 
sICH. The Mann-Whitney U comparison does not assess directionality, but 
it is clear that exceeding this fixed SBP threshold does not correlate with 





In this study of 90 patients with LVO stroke undergoing thrombectomy, we showed that 
continuous estimation of optimal blood pressure and limits of cerebral autoregulation is 
feasible. We further demonstrated that exceeding individual and flexible thresholds of 
autoregulation is associated with hemorrhagic transformation and overall worse functional 
outcome, even after adjusting for important prognostic covariates in stroke. Every 10% 
increase in time spent above ULA was associated with a 1.9-fold increase in the odds of 
shifting towards a worse outcome on the mRS at 90 days. We did not find this association 
when applying fixed blood pressure thresholds, even when stratifying by reperfusion status. 
 
To date, there are no randomized controlled trials of optimal blood pressure management 
after EVT, and data to guide treatment approaches are limited. The majority of patients 
enrolled in recent thrombectomy trials also received intravenous tPA and were managed 
according to current guidelines with blood pressure below 180/105 mmHg for 24 hours. 
[207, 209, 210, 213, 229] However, recanalization rates with EVT are much higher 
compared to intravenous thrombolysis alone, and it remains unclear if the same BP targets 
apply. While a higher BP may be acceptable or even beneficial in patients with incomplete 
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reperfusion by promoting perfusion to ischemic territories, it could lead to relative 
hyperperfusion with consequent cerebral edema and hemorrhage in those patients with 
complete reperfusion. This phenomenon is well described in chronic ischemia after carotid 
revascularization (via endarterectomy or stenting) but may also occur in acute stroke. [230-
232] Indeed, Hashimoto et al. presented a case of cerebral hyperperfusion syndrome in 77-
year-old patient with acute internal carotid and middle cerebral artery occlusions. Due to 
the patient’s neurologic deterioration, the authors suggest that it is important to routinely 
monitor regional oxygen saturation with NIRS, perform single-photo emission CT to 
evaluate cerebral blood flow, and maintain antihypertensive therapy to prevent 
hyperperfusion after revascularization. It is also possible that this complication is more 
prevalent than the handful of published and available case reports might suggest. [232] 
 
Several thrombectomy trials, therefore, used a tiered approach with lower BP targets if 
successful reperfusion was achieved. [208, 211, 212, 232] However, we did not find a 
correlation between BP above these limits and any of our radiographic or clinical 
outcomes. (A minor exception in Table 24 is that patients with sICH spent significantly 
less time above 120 mmHg. Because patients with sICH spent less time above this 
threshold, the p-value of 0.037 does not argue in favor of using a fixed systolic threshold, 
as the directionality of this association does not align with the physiologic assumption that 
higher pressures underlie HT and sICH.) Still, optimal BP ranges after EVT are likely 
influenced by numerous factors; stratifying by reperfusion status alone may be insufficient. 
For example, chronic hypertension and flow-limiting extracranial carotid disease can shift 
a patient’s autoregulatory curve towards higher pressures, and aggressively lowering BP 
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after successful EVT in such a patient may result in cerebral hypoperfusion and infarct 
expansion. [233, 234] In contrast, optimal BP may shift towards lower targets among 
patients without a history of hypertension or pre-existing large-vessel disease.  
 
Our data also suggests that limits of autoregulation are not static, but rather change over 
time; thus, maintaining the same BP target throughout the acute phase of ischemic stroke 
may lead to frequent episodes of hypo- and hyperperfusion. Figure 24 shows an example 
of a patient whose BP remained below the guideline-recommended target but frequently 
exceeded personalized autoregulatory limits. In addition, the patient’s BP was above the 
lower BP threshold of 140 mmHg for almost the entire monitoring period. However, BP 
lowering in this particular patient may lead to a decrease below the LLA with consequent 
risk of ischemia. While there appears to be general trend towards worse outcome with 
increasing time above SBP thresholds of 140 mmHg and 160 mmHg, the effect sizes were 
much smaller when compared to the personalized, autoregulation-based approach. 
Moreover, they became non-significant when adjusting for covariates. These findings 
suggest that selecting a single BP target for all patients may not sufficiently account for 
patient-specific factors affecting cerebral perfusion. Therefore, taking into consideration 
individual patients’ hemodynamic physiology and maintaining BP within autoregulatory 
targets may be a better strategy compared to the classical approach of maintaining SBP 
below fixed, pre-determined values. 
 
To explore possible mechanisms underlying the association of BP outside autoregulatory 
limits and poor outcome, we evaluated several short-term imaging endpoints that have 
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strong associations with outcome after stroke. Time spent above the ULA, but not any of 
the fixed SBP thresholds, was associated with higher rates of HT. This finding is supported 
by the construct that above the ULA, cerebral vasculature acts as a pressure-passive system, 
in which increases in cerebral blood flow are not counteracted by vasoconstriction, 
resulting in periods of hyperperfusion. Furthermore, higher cerebral blood flow after 
reperfusion therapy, measured with arterial spin labeling MRI, has been shown to increase 
risk of HT. [235] In addition, several retrospective studies reported an association between 
elevated BP after thrombectomy and HT, [224, 236] although others did not find this 
association. [223] Differences in autoregulatory function may be one explanation for 
conflicting results. In our study, elevated BP relative to each patient’s personalized ULA 
was associated with increased risk of sICH and neurologic worsening, rather than absolute 
increased BP alone. This hypothesis is succinctly summarized in the illustration below 







Figure 26. Relative hyperperfusion above the ULA may predispose patients 
to hemorrhagic transformation and worse outcomes. In contrast, patients 
who oscillate within their personalized limits of autoregulation may be 
protected from secondary brain injury after stroke.  
 
 
BP management below the LLA was associated with greater infarct progression, 
suggesting that the sustenance of the ischemic brain tissue may be improved by maintaining 
cerebral perfusion above the LLA. In addition to subtotal reperfusion and autoregulatory 
impairment, microcirculatory dysfunction and distal embolization are possible 




This study has several important limitations. First, the sample size was modest, and while 
the study was significant for its primary outcome, we were not able to adjust for all 
predictors of poor outcome. The addition of short-term radiographic endpoints and a 
plausible biological mechanism help mitigate this limitation. Second, 12 patients enrolled 
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toward the beginning of our study were excluded from analysis due to insufficient 
recording time or poor signal quality. Technical challenges faced at the beginning of the 
study have since been overcome. Third, 3-month outcomes were available for only 86.7% 
(78/90) of patients. However, both groups (patients with and without 3-month outcomes) 
were comparable in terms of baseline characteristics (Table 25). Furthermore, a sensitivity 
analysis imputing 3-month outcomes using the last-observation-carried-forward approach 
resulted in similar associations and effect sizes between BP targets and outcome (Table 
26). Finally, information produced from this study is descriptive and correlational; 
causation cannot be inferred. Conclusions about whether an autoregulation-guided therapy 
protocol will improve patient physiology or outcome are not possible at this stage. 
 
Table 25. Comparison between patients with and without 3-month 
longitudinal outcome measures (90-day mRS) 
Variable Patients with 90-





Age, mean ± SD 72.2 (16.1) 67.5 (17.6) 0.348 
Sex, F (%) 37 (47.4) 5 (41.7) 0.709 
Admission NIHSS, mean ± 
SD 
14.2 (5.8) 11.7 (4.3) 0.134 
Admission ASPECTS, mean 
± SD 
8.8 (1.5) 8.4 (2.3) 0.974 
Admission MAP, mean ± SD 107.4 (17.1) 106.8 (19.2) 0.967 
Admission Glucose, mean ± 
SD 
140.2 (72.4) 118.3 (24.2) 0.188 
Affected Side, n (%) 
     Left 









Medical History, n (%) 
    Hypertension 
    Coronary Artery Disease 
    Myocardial Infarction 
    Congestive Heart Failure 
    Atrial Fibrillation 
    Hyperlipidemia 



























    Ischemic Stroke 
    Cancer 
    Thyroid Disease 
    Current Smoker 
















Mean monitoring time 
(hours), mean ± SD 
28.4 (18.7) 25.1 (16.6) 0.749 
Percent time MAP within 
limits of autoregulation, 
mean ± SD 
66.6 (22.6) 60.3 (25.4) 0.433 
Percent time MAP above the 
upper limit of autoregulation, 
mean ± SD 
15.6 (11.9) 22.8 (20.0) 0.226 
Percent time MAP below the 
lower limit of autoregulation, 
mean ± SD 
18.1 (15.7) 17.0 (11.0) 0.803 
Mean MAP (mmHg), mean 
± SD  
93.1 (12.0) 97.6 (12.9) 0.141 
Mean upper limit of 
autoregulation (mmHg), 
mean ± SD 
104.4 (11.6) 107.2 (11.2) 0.302 
Mean lower limit of 
autoregulation (mmHg), 
mean ± SD 
83.2 (11.7) 87.2 (14.1) 0.302 
Mean MAPOPT (mmHg), 
mean ± SD 
93.1 (11.8) 95.0 (13.6) 0.522 
Treated with tPA, n (%) 33 (42.3) 5 (41.7) 0.967 
Time to reperfusion 
(minutes), mean ± SD 
582.4 (420.4) 532.6 (321.1) 0.834 
Successful recanalization, n 
(%)  
59 (75.6) 8 (66.7) 0.494 
TICI Score, n (%) 
     0 
     1 
     2a 
     2b 





















      HT I 
      HT II 
      PH I 
      PH II 

















transformation, n (%) 
7 (9.0) 1 (8.3) 1.000 
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Cerebral edema, n (%) 9 (11.5) 1 (8.3) 1.000 
Final infarct volume (mL), 
mean ± SD 
82.1 (86.6) 79.4 (72.9) 0.747 
Infarct progression (mL), 
mean ± SD 
80.2 (83.0) 71.9 (80.5) 0.722 
 
Table 25. Univariate comparison between patients with longitudinal 3-
month mRS outcomes and the subgroup of those patients who were lost to 
follow-up. Significant differences were determined using independent 
student’s T-tests and chi-squared analysis for normally distributed data, 
while Mann-Whitney U tests were used for non-parametric variables. 




Table 26. Last-observation-carried-forward sensitivity analysis 
Likelihood of a shift towards worse outcome on 90-day mRS 




1.7 1.2-2.3 0.002 1.7 1.2-2.3 0.002 
%time MAP 
within LA, per 
10-percent 




1.3 0.9-1.6 0.064 1.2 0.9-1.6 0.154 
 
Table 26. Last-observation-carried-forward sensitivity analysis of 
outcomes at 90-days. aOR, adjusted odd ratio (adjusted for age, admission 
NIHSS, ASPECT score, and TICI score); OR, odds ratio; MAP, mean 
arterial pressure; mRS, modified Rankin scale; ULA, upper limit of 
autoregulation; LA, limits of autoregulation; LLA, lower limit of 
autoregulation; CI, confidence interval.  
 
 
Conclusion of the ischemic stroke neuromonitoring study 
 
Continuous estimation of limits of autoregulation after EVT is feasible and provides a BP 
range for individual patients tailored to their own physiology. Exceeding LA, but not fixed 
SBP thresholds, was associated with HT as well as overall poor functional outcome. This 
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information is particularly important in the evolving landscape of endovascular treatment 
approaches, in which more patients will require early management in neurological 
intensive care units. Further research is needed to test autoregulation-based treatment 
strategies – namely, a multicenter randomized controlled trial comparing our personalized 
autoregulatory approach to the guideline-recommended practice of maintaining SBP below 






A. Concluding remarks and future studies 
 
Continuous neuromonitoring of cerebral autoregulation can be harnessed for bedside 
individualization of blood pressure care in critically ill patients. The past two decades have 
ushered in numerous reports on the clinical import of autoregulation and optimal cerebral 
perfusion pressure monitoring. Although these studies wield considerable disparities in 
methodology, patient population, and sample size, the vast majority demonstrate that 
dysfunctional cerebral autoregulation plays a key role in secondary brain injury after 
neurologic disease. As discussed throughout this thesis, this concept holds true for patients 
suffering from subarachnoid hemorrhage and ischemic stroke. Complications like DCI and 
HT are potentially devastating turning points during a given patient’s hospitalization, and 
so any approach to predict and prevent them should be prioritized and rigorously evaluated 
in a randomized fashion. In Part II, our study on subarachnoid hemorrhage shows that 
deviation from individualized limits of autoregulation strongly associates with poor 
functional outcome at discharge and 90 days after the initial bleed. The study further 
demonstrates collinearity between invasive (ICP) and non-invasive (NIRS) measures of 
autoregulation. In Part III, our study on ischemic stroke shows that exceeding the upper 
limit of autoregulation correlates with worse functional outcome as well as worsening 
grades of HT. The study further compares our personalized approach to currently 
recommended fixed systolic thresholds and argues for future research in prospective, 
multicenter, and randomized trials. On the whole, these two studies regarding subarachnoid 




In fact, we are currently planning a pilot trial to test the feasibility of an intervention 
protocol targeting a dynamic MAPOPT. We will test the hypothesis that blood pressure 
adjustments during periods of dysautoregulation can restore autoregulatory function by 
shifting patients to a more favorable position on the autoregulatory curve (Figure 27A). 
Under the null hypothesis, the treatment would lower blood pressure but also the limits of 
autoregulation, shifting the autoregulatory curve to the left. As a result, MAP would never 
return to within limits of autoregulation (Figure 27B). Under the alternative hypothesis, 


















































































































In this future study, patients with LVO ischemic stroke will receive personalized blood 
pressure recommendations every 6 hours to maintain MAP within personalized limits of 
autoregulation during the first 24 hours after LVO stroke. During the first 2 hours after 
enrollment, patients will be managed according to American Heart Association guidelines 
with BP <180/105 mmHg, bridging the time for ICM+ software to provide the first flexible 
MAP target. MAPOPT will be assessed every 6 hours by the treating clinicians. An 
automated alert will ask the treating clinicians to review and set the new individual and 
flexible MAP target. If no MAPOPT can be set for any variety of reasons (e.g., non-parabolic 
curve generation), the default clinical target (BP <180/105) will be used. To minimize risk 
of harm, MAP <60 or MAP >120 mmHg will not be targeted (predefined safety ranges). 
The treatment strategy to support arterial blood pressure will include blood pressure 
augmentation using intravenous fluids and/or vasopressors as a second-line approach, as 
well as active pharmacological lowering of blood pressure with antihypertensive 
medication (e.g., labetalol or metoprolol).  
 
Although it may be possible to target the optimal blood pressure range in real-time, we will 
use regular intervals for data review, during which new blood pressure targets will be 
selected based on data from the prior 6 hours of monitoring. Blood pressure targets selected 
this way closely resemble a person’s real-time autoregulatory limits (Figure 28). In 
addition, this approach adds an extra layer of safety, as treating clinicians would 
periodically review the data, such that they could always decide not to follow the MAPOPT 










Lastly, future studies may approach the patient from a broader physiologic perspective, as 
several hemodynamic parameters influence cerebral blood flow (not merely blood 
pressure). In fact, since mean arterial pressure is dependent on cardiac function, 
optimization of cardiac output might be an alternative, or perhaps adjunctive, approach in 
the effort to optimize cerebral perfusion pressure. It has been shown that cerebral perfusion 
depends on cardiac output in ischemic dysregulated brain territories. [239] Noting that 13-
28% of stroke patients sustain cardiac contractility impairment, another study found that 
cerebral blood flow was significantly higher in patients with preserved left ventricular 
contractility. [240] A more recent study by Fuhrer et al. assessed cerebral perfusion in 10 








































patients with acute large hemispheric strokes, alongside their mean arterial pressures and 
cardiac indices. [241] The latter hemodynamic parameter strongly correlated with cerebral 
perfusion, whereas correlation with blood pressure was not observed. Despite limitations 
(particularly the sample size), the authors go so far as to propose a paradigm shift – namely, 
their results might challenge the current state of using blood pressure as the main clinical 
roadmap in the intensive care of patients with cerebral ischemia. Rather, they advocate for 
a cardiac output-guided hemodynamic strategy. This strategy is supported by basic 
physiology. After all, mean arterial pressure is the product of cardiac output and systemic 
vascular resistance, and cardiac output depends on other factors like preload, contractility, 
and heart rate. Blood pressure is just the afterload. To increase cardiac output, these 
parameters can be augmented with intravenous fluids or catecholamine administration, all 
in accordance with the Frank-Starling curve. Because the correlation between blood 
pressure and cardiac output is volume state dependent, the focus on blood pressure to 
improve brain oxygen delivery and perfusion may hold true only in the setting of 
isovolemia. With these basic principles in mind, the same team at the University of 
Freiburg has launched a multicenter randomized trial, entitled Optimizing Cardiac Out-Put 
to Increase Cerebral Penumbral Perfusion in Large Middle Cerebral Artery Ischemic 
Lesion (OPTIMAL Study). [242] The two arms seek to enroll 150 patients each and 
compare functional outcome at 3 and 6 months. The trial is in part based upon optimization 
of cardiac output in patients with severe subarachnoid hemorrhage. In those studies, 
increasing cardiac output, while keeping mean arterial pressure constant, led to higher 
cerebral blood flow readings, diminished rates of delayed cerebral ischemia, and improved 
functional outcomes. [243, 244] As we await the results of the OPTIMAL trial in stroke 
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patients, it is important to note that future surveillance and optimization of cardiac output 
may become an integral facet of acute stroke care. Regardless of a possible paradigm shift 
towards cardiac output, the ultimate goal of all of these trials will be to prevent penumbral 
injury, improve collateral flow, and maximize perfusion and sustenance to impaired brain 
tissue.  
 
This is all to say that the heart-brain axis is highly complex, with many moving parts and 
puzzle pieces, and so the future will likely favor real-time, multimodal hemodynamic and 
neuromonitoring of critically ill patients. Nevertheless, our autoregulatory avenue appears 
extremely promising and is illuminated with the lampposts of many provocative studies, 
including those presented herein. We hope this path will intersect and merge with other 
branches of cardiovascular neurology, as a synergistic effort will likely lead to the best 
possible outcomes.  
 
To conclude and summarize the results of this thesis, our group effectively demonstrated 
that individualized blood pressure targeting represents a highly feasible approach in the 
neuroscience intensive care unit. Using cerebral autoregulation monitoring, we were able 
to define and trend personalized pressure thresholds in real-time, across two different 
disease states. The primary outcome of both the subarachnoid hemorrhage and ischemic 
stroke studies pertained to the impact of deviation from those thresholds on radiographic 
and functional outcomes. In the subarachnoid hemorrhage study (Part II), deviating from 
autoregulatory limits strongly associated with functional outcome, and invasive and non-
invasive measures of autoregulation demonstrated collinearity. In the ischemic stroke study 
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(Part III), exceeding the upper limit of autoregulation – but not any of the fixed systolic 
thresholds – correlated with functional outcome and hemorrhagic transformation. At this 
exciting juncture, many future directions are possible, but the local stage is set for an 
interventional trial at Yale-New Haven Hospital, in which our team will titrate pressures 
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